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The	NHMRC	Clinical	Trials	Centre	at	the	University	of	Sydney	runs	large	multicentre	
investigator-initiated	clinical	trials,	takes	part	in	trials	of	national	and	international	collaborative	
trial	groups	and	contributes	expertise	to	trials	run	by	others.	It	also:
•	 undertakes	research	into	trial	methods	and	is	recognised	through	publications	as	a	leader	in	
trial	methodology
•	 reviews	and	synthesises	evidence	from	completed	trials,	and	is	at	the	forefront	of	
developments	in	methods,	such	as	prospective	meta-analysis
•	 advises	on	trial	design	and	operation,	and	randomises	patients	and	analyses	data	for	other	
groups	conducting	trials,	particularly	through	its	Outreach	program
•	 takes	a	lead	in	proposing	new	directions	for	trial	research	in	Australia,	particularly	with	regard	
to	integrating	clinical	trials	with	national	policy	and	clinical	practice
•	 offers	placements	for	postgraduate	students	in	all	of	these	areas
•	 runs	short	courses	in	the	design	and	conduct	of	clinical	trials	as	part	of	its	undertaking	to	train	
people	for	Australian	medical	research.	
Core	funding	is	provided	by	the	NHMRC,	and	specific	projects	are	funded	by	government,	public	
and	private	institutions	and	the	pharmaceutical	industry.	
The	CTC	is	at	two	sites	in	Camperdown	in	inner	Sydney	—	the	Medical	Foundation	Building	on	
Parramatta	Road	and	on	Mallett	Street.
This	report	covers	the	CTC’s	achievements	for	the	biennium	2008–2009.
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20-years	on
In	2009	we	celebrated	our	20	years	of	research	and	
evidence	with	a	one-day	symposium.	Leaders	from	
academic	and	research	institutions	and	government	
underscored	the	fundamental	role	of	trials	research	in	
clinical	practice,	policy	and	health,	and	explored	the	likely	
way	ahead.	Australia	faces	rapid	aging	of	the	population	
coupled	with	increases	in	the	cost	and	sophistication	
of	both	health	care	and	medical	research.	In	addition,	
biological	and	genetic	clinical	research,	which	can	lead	to	
personalised	care	for	patients,	will	raise	new	challenges.	
The	CTC	and	its	collaborators	are	in	a	strong	position	
to	contribute	to	Australia’s	health	research	over	the	
coming	years.	From	a	handful	of	staff	in	1988,	the	CTC	
has	grown	to	about	150	in	2009.	Government	grant	
funding	for	the	two	years,	2008–2009,	was	over	$24	
million,	supplemented	by	substantial	funding	won	
from	industry	for	clinical	trials.	Dedicated	research	staff	
and	increasing	funds	have	led	to	success	in	publication:	
in	2008–2009,	we	contributed	to	over	90	published	
research	articles,	most	in	high-impact	journals,	and	9	
reports	for	government.	CTC	staff	gave	over	80	research	
presentations	at	national	and	international	conferences.	
CtC	executive:	wendy	Hague	(clinical	trials	program	director),	kim	russell-Cooper	(general	manager),		
anthony	keech	(deputy	director)	and	John	simes	(director).
We	have	been	at	the	forefront	of	research	on	new	
treatments	and	establishing	the	optimal	use	of	existing	
treatments.
Central	to	the	success	of	these	activities	have	been	the	
extensive	networks	of	collaborators	we	work	with	and	
our	strong	and	enduring	partnerships	with	government,	
nongovernment	organisations	and	industry.	We	actively	
work	with	7	collaborative	groups	in	oncology	on	current	
trials	and	participate	in	other	projects	more	broadly.	Our	
research	covers	cancer	types	representing	about	75%	
of	the	cancer	disease	burden	in	Australia.	A	grant	from	
Cancer	Australia,	together	with	other	grants,	has	helped	
us	to	establish	new	collaborative	groups	and	to	appoint	
a	new	chair	in	health	economics,	Professor	Deborah	
Schofield.	
In	collaboration	with	associated	groups	we	currently	
have	over	50	trials	open	to	recruitment,	in	follow-up	
or	about	to	commence.	Completed	trials	have	resulted	
in	many	exciting	discoveries.	In	FIELD,	the	finding	that	
fenofibrate	can	reduce	the	risk	of	amputation	and	damage	
from	small-vessel	disease	opens	up	a	new	treatment	
option	for	patients.	The	SNAC	trial	showed	that	sentinel-
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node-biopsy-based	management	of	early	breast	cancer	leads	to	
better	quality	of	life	and	less	arm	morbidity	than	more	extensive	
surgery	of	the	axilla.	In	advanced	colorectal	cancer,	the	K-ras 
gene	type	can	now	identify	patients	who	will	benefit	from	
cetuximab,	a	molecular	targeted	therapy	(C0.17	trial).	In	LIPID,	
novel	biomarkers	linked	to	coronary	risk	have	been	identified,	
and	a	study	differentiating	measurement	error	and	true	change	
in	cholesterol	monitoring	revealed	that	much	routine	testing	
could	be	too	frequent.	
One	of	our	research	strengths	is	to	devise	new	methods	and	
apply	them	to	trial	datasets	to	strengthen	and	augment	trial	
findings.	A	major	international	prospective	meta-analysis	of	the	
Cholesterol	Treatment	Trialists’	Collaboration,	coordinated	by	
the	CTC	and	the	Clinical	Trials	Service	Unit,	Oxford,	confirmed	
the	benefits	of	statin	therapy	in	patients	with	diabetes	in	an	
individual-patient-data	analysis	of	a	cohort	from	14	trials.	A	
neonatal	meta-analysis	study	showed	that	unrestricted	oxygen	
therapy	for	premature	infants	had	potential	harms	without	
clear	benefits.	This	practice	has	been	abandoned,	but	more	
targeted	oxygen	therapy	is	being	assessed	in	ongoing	trials	
(BOOST	II).	Risk	models	and	improved	methods	for	diagnostic	
test	evaluations	have	allowed	better	application	of	new	
evidence	from	trial	data	to	individual	patients.	For	example,	
a	study	of	complex	measures	of	test	accuracy	combined	with	
available	clinical	evidence	has	determined	the	incremental	
accuracy	of	magnetic	resonance	
imaging	and	its	potential	
contribution	to	cancer	staging.	
All	of	the	research	we	undertake	
at	the	CTC—either	by	generating	
relevant	evidence	through	
appropriate	trials	or	by	developing	
better	methods	for	integrating	trial	
evidence	and	other	information—	
is	based	on	ensuring	that	trial	
evidence	will	have	optimal	impact	
on	future	practice	.	These	pages	
report	many	examples	of	clinical	
trials	and	related	research	that	
should	lead	to	improvements	
in	health	outcomes	from	future	
changes	in	clinical	practice	and	
health	policy.	
JoHn	SImES
Director
professor	John	Simes	is	
the	foundation	director	
of	the	ctc	and	represents	
the	ctc	on	many	national	
and	international	
committees.	In	2009,	he	
received	the	distinguished	
Alum	Award	from	the	
department	of	Biostatistics	at	the	Harvard	School	
of	public	Health.	professor	Simes	is	also	a	specialist	
medical	oncologist	at	royal	prince	Alfred	Hospital.	
AntHony	KEEcH
Deputy director
professor	Keech,	
cardiologist	and	
epidemiologist,	co-
directs	the	ctc	research	
program.	He	is	chairman	
of	the	field	study	
on	heart	disease	and	
diabetes.	As	a	professor	
in	the	department	of	medicine	at	the	university	
of	Sydney,	he	initiates,	coordinates,	develops	
and	teaches	courses	for	medical	and	other	
postgraduate	students.	professor	Keech	is	also	a	
practising	consultant	cardiologist	at	royal	prince	
Alfred	Hospital.
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In 2008 the CTC moved from the 
Mallett Street campus to two sites in 
Camperdown, the Medical Foundation 
Building, 92–94 Parramatta Road,  
and 6–10 Mallett Street.
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20	years	of	the	nHmrc	clinical	trials	centre
tHe	first	deCade
The	CTC	was	founded	in	October	1988	in	response	to	
a	national	need	for	relevant	evidence	to	underpin	the	
individual	clinical	decisions	of	Australian	doctors.	The	
National	Health	and	Medical	Research	Council	funded	
the	centre	at	the	University	of	Sydney,	on	the	basis	of	
its	international	reputation	as	a	centre	of	excellence	in	
medical	research,	diverse	research	infrastructure,	and	large	
departments	of	public	health	and	medicine.	
Work	began	with	two	staff:	Dr	John	Simes,	the	
director,	and	his	assistant.	Within	a	year,	the	CTC	had	
acquired	biostatisticians,	computer	systems	experts,	trial	
coordinators,	research	fellows	and	a	deputy	director.	By	
the	end	of	1989,	two	international	cardiovascular	trials,	
LIPID	and	the	TPA/SK	mortality	trial,	and	several	large	
cancer	trials	were	up	and	running,	with	over	2000	patients	
recruited.
From	the	start,	the	centre’s	educational	role	was	
central	to	its	goals	of	improving	the	quality	of	clinical	trials	
in	Australia	and	being	relevant	to	clinical	practice.	For	the	
staff,	this	meant	teaching	and	supervising	postgraduate	
students	and	turning	out	short	courses	in	statistics	and	
trial	management.
By	1996,	trials	in	germ	cell	cancer,	breast	cancer	and	
cardiovascular	disease	were	operational,	and	several	
million	dollars	in	annual	funding	flowed	from	industry	and	
government.	Growing	staff	numbers	prompted	the	move	
from	the	university	campus	to	the	Mallett	Street	campus	
in	December	1996.	
Between	1997	and	1998,	the	CTC	began	to	take	on	
more	trials	and	branched	out	into	trials	methodology.		
It	also	developed	its	advising	and	consulting	role.
tHe	seCond	deCade
The	number	and	breadth	of	the	trials	increased	and	
included	important	initiatives	in	neonatal	research.	
Research	into	trials	methodology	led	to	better	ways	of	
designing	and	conducting	trials.	Data	from	continuing	
and	completed	trials	became	a	rich	source	for	analysis	in	
substudies,	secondary	studies	(such	as	cost-effectiveness	
analyses)	and	meta-analyses.	Research	activities	that	
added	value	to	trial	results	became	an	important	focus.	
Memorable	highlights	of	this	period	were	the	
international	clinical	trial	symposiums,	in	1999,	2002	
and	2007,	and	the	long-awaited	Australian	New	Zealand	
Clinical	Trials	Registry,	established	in	2005.
tHe	tHird	deCade
Now,	about	150	people	work	at	the	CTC.	Current	trials	
range	from	about	50	patients	in	some	of	the	cancer	
treatment	trials	to	thousands	still	being	followed	up	in	
the	international	FIELD	diabetes	trial.	The	CTC’s	first	
major	multicentre	trial,	LIPID,	is	still	following	up	nearly	
7000	patients	of	the	original	9014,	19	years	from	its	first	
randomisation.	
The	CTC	remains	focused	on	the	future.	In	part	
because	of	clinical	trials	of	past	years,	Australians	are	
living	longer,	so	their	health	needs	may	be	changing.	
For	example,	cancer	survivors	want	better	quality	of	
life.	In	the	CTC’s	third	decade,	the	issues	will	be:	how	to	
conduct	more	trials	in	Australia	in	the	face	of	cost	barriers;	
how	to	make	trials	research	an	integral	part	of	health	
care;	going	beyond	drug	trials	to	assess	other	types	of	
therapy;	finding	out	how	individual	patients	respond	
to	treatment,	in	biotechnology	and	preference	studies;	
and	answering	important	clinical	questions	in	new	areas	
(such	as	indigenous	health).	Future	progress	will	rely	on	
collaboration	among	many	research	networks	as	well	as	
groups	in	universities,	government	and	industry.	
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In	2008	the	Clinical	Trials	Centre	
reached	a	milestone:	20	years	
of	research	generating	evidence	
for	high-quality	health	care.	At	a	
celebration	symposium,	leaders	from	
government,	industry,	research	and	
the	community	at	large	reviewed	
past	and	recent	trial	successes	and	
addressed	the	following	questions	
and	issues	concerning	the	next	20	
years.	
Research	is	likely	to	be	shaped	
by	the	continued	aim	of	improving	
practice	and	health	outcomes,	
but	with	new	challenges	and	
constraints—particularly	the	need	
for	even	larger	patient	numbers	
to	reliably	demonstrate	treatment	
benefits;	the	ever-increasing	costs	
of	new	trials	and	developing	new	
treatments;	the	growing	demands	of	
regulatory	and	ethical	requirements;	
and	the	challenges	and	opportunities	
associated	with	new	technologies,	
especially	molecular	targeted	
therapies	and	e-health.	Trials	need	
careful	planning	and	conduct	to	
ensure	that	we	get	the	best	evidence	
and	that	it	can	be	applied	effectively	
where	it	is	needed.	Central	to	this	is	
answering	the	right	clinical	questions	
in	the	most	efficient	and	effective	
ways.	
How	Can	we	make	sure	tHat	
CliniCal	trials	ask	tHe	rigHt	
questions?
This	is	a	complex	issue	and	involves	
clinical	investigators	with	relevant	
trial	expertise	working	with	basic	
scientists	(helping	to	identify	
potential	new	treatments),	clinicians	
(with	knowledge	of	current	best	
standard	care)	and	patients	or	
consumers	(to	ensure	questions	
relevant	to	the	patients’	perspective	
are	addressed).	Prioritising	potential	
trials	will	also	depend	on	the	burden	
of	disease	(from	national	morbidity	
statistics),	knowing	which	studies	
are	already	being	done	(from	trial	
registers),	and	reviews	of	current	
evidence	(defining	best	care	and	
ensuring	questions	have	not	already	
been	answered).	
wHat	will	affeCt	data		
and	metHods	in	tHe	next	20	
years?
As	clinical	research	progresses,	
patients	participating	in	trials	are	
healthier,	so	trials	seek	smaller	
incremental	improvements	from	
treatment.	This	means	that	larger	
numbers	of	participants	are	needed	to	
show	a	difference.
Added	to	this,	patients	can	now	
be	stratified	by	biological	markers	
into	smaller	groups	to	allow	more	
personalised	use	of	therapies	
according	to	individual	profiles.	For	
example,	many	new	cancer	therapies	
are	particularly	effective	but	for	only	
a	subgroup	of	patients,	depending	on	
the	genetic	make-up	of	the	cancer.	
This	means	we	have	the	challenge	
of	finding	sufficient	patients	for	each	
new	trial	as	well	as	less	return	on	cost	
from	the	developed	therapies	(due	to	
the	smaller	future	market).
Triallists	are	already	faced	with	
the	quandary	that	patients	are	
very	different:	there	may	be	more	
biological	markers	and	genetic	
factors	in	the	patients	than	there	
are	types	of	event	to	be	measured.	
This	has	implications	for	methods	
and	trial	operation.	First,	methods	
of	incorporating	prognostic	and	
predictive	biomarkers	will	be	
important.	Second,	tissue	banking	
and	blood	sampling	should	be	a	
routine	part	of	trials	(with	appropriate	
ethical	and	privacy	safeguards),	so	
that	samples	can	be	tested	in,	say,	
10	years’	time,	after	other	treatment	
discoveries.	Synthesising	that	
information	requires	novel	methods.
effiCienCy	is	a	goal		
in	trials	researCH
Appropriate	trial	design	can	maximise	
efficiency.	The	event	or	disorder	being	
measured	in	a	trial	has	to	be	frequent	
enough	to	allow	valid	statistical	
analysis.	Combining	various	types	of	
clinical	event	and	looking	at	the	total	
(a	composite	outcome)	leads	to	more	
statistical	power	and	more	ability	to	
show	an	effect.	Combining	several	
smaller	studies	can	be	an	alternative	
to	very	large	trials.	Systematic	reviews	
of	evidence	and	prospective	meta-
analysis	are	established	but	evolving	
methods	for	obtaining	evidence	from	
combined	studies.	For	this	to	work,	
all	trials	must	be	registered	so	that	
none	are	excluded.	Data	can	also	be	
combined	and	reanalysed	with	data	
from	past	trials,	a	method	that	is	
particularly	useful	when	augmented	
by	new	knowledge,	as	in	studies	of	
new	biomarkers.	
Strategies	to	maintain	clinical	
research	will	require	ways	of	reducing	
its	considerable	expense.	Regulatory	
requirements,	ethical	requirements,	
contracts,	insurance	and	so	on	are	
great	administrative	burdens	for	
research.	We	need	to	ensure	that	
those	demands	are	no	more	than	in	
routine	clinical	practice.	
The	types	of	trials	that	obtain	
pharmaceutical-industry	funding	are	
those	with	a	potential	commercial	
return.	The	private	sector	model	has	
the	advantage	that	only	treatments	
that	work	are	likely	to	be	developed,	
but	the	drawback	is	that	useful	
treatments	without	commercial	
20	years	of	clinical	trials:	a	symposium
new	evidence,	better	treatment,	changed	practice
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value	can	be	neglected.	Therefore,	
trials	research	that	improves	health	
presupposes	that	some	of	the	funding	
must	come	from	government.	
Making	clinical	trials	a	routine	
part	of	clinical	practice	would	lead	
to	administrative	efficiency	and	thus	
lower	costs.	One	of	the	main	costs	of	
research	is	generating	and	accessing	
data.	Electronic	medical	records	could	
allow	every	patient	to	contribute	
to	research	evidence	by	linking	
streamlined	pragmatic	or	even	virtual	
trials	into	health	records.	
Governments	may	fund	
studies	because	it	would	be	more	
cost-effective	than	paying	for	
services	without	evidence	of	their	
effectiveness	and	value.	For	other	
activities,	an	idea	worth	exploring	is	
global	health	research	fund	that	could	
require	investment	from	government	
and	industry	to	support	questions	of	
major	public	health	importance.
trials	in	Hard-to-researCH	
areas:	a	CHallenge	
to	Current	funding	
arrangements
Trials	that	go	beyond	drugs	—	such	
as	physical	interventions,	systems	
of	care,	rehabilitation	programs,	
paediatric	trials	and	surgery	—	often	
do	not	fit	a	commercial	model,	so	
governments	need	to	fund	them	
directly	or	improve	the	regulatory	
framework	for	industry	to	do	so.	One	
example	where	this	has	been	done	is	
in	the	United	States,	where	licences	
for	certain	drugs	have	been	extended	
in	return	for	a	commitment	to	use	
them	in	paediatric	trials.
How	Can	trials	beCome	
more	relevant	to	CliniCal	
PraCtiCe?
Evidence	will	not	be	applied	if	the	
clinical	outcomes	do	not	reflect	the	
full	clinical	picture:	averting	clinical	
events	or	improving	survival	may	not	
be	enough	without	quality	of	life.	In	
addition	to	this,	the	trial	evidence	
must	be	relevant	to	individuals.	Our	
methods	must	include	exploring	the	
generalisability	of	results	and	the	
individual	differences	among	patients.	
Evidence-based	management	
of	patients	as	a	criterion	of	hospital	
performance	would	improve	the	
application	of	evidence	to	practice	
generally.	One	current	example	is	
the	use	of	statins,	beta-blockers	
and	anticoagulants	in	protocols	of	
treatment	after	myocardial	infarction.
will	CliniCal	trials	remain	
viable	in	australia?
The	growing	costs	for	trials	research,	
whether	by	the	pharmaceutical	
industry	or	cooperative	trial	groups,	
relate	to	ethics	and	governance	as	
well	as	conduct	of	trials.	Australia	
will	have	difficulty	competing	on	
costs,	but	by	starting	small	with	a	
grant	from	government	for	capacity	
building	or	part	of	a	trial,	we	can	
build	a	framework	of	expertise	and	
knowledge	for	major	international	
trials.	Australia’s	advantage	is	quality.	
Although	local	patients	may	be	
scarce,	we	have	the	opinion	leaders,	
the	intellectual	resources,	and	the	
ability	to	design	and	analyse	studies	
and	undertake	biological	substudies.	
These	attest	to	a	capacity	to	continue	
to	generate	new	evidence	for	better	
treatment	and	changed	practice	in	
the	next	20	years.
below:	20-year	symposium	
panellists,	warwick	anderson,	chief	
executive	officer	of	the	nHmrC;	
sally	Crossing	(centre),	representing	
health	care	consumers;	and	kevin	
lynch,	Celgene	australia.
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funder 2008 2009
NHMRC
Program	grant 1,543,752 1,574,627
Project	grants 2,823,502 4,891,661
Fellowships 283,250 383,000
Public	funding	for	technology	assessment	and	systematic	reviews 632,841 1,114,865
Cancer	Australia	and	cancer	councils 4,361,427 4,702,732
Cancer	Institute	NSW 816,694 1,221,872
National	Heart	Foundation 63,000 64,500
Other	public	funders 143,727 178,087
Pharmaceutical	industry* 4,157,573 4,753,448
Biostatistics	Collaboation	of	Australia	and	workshops 322,232 316,418
Collaborative	projects 1,008,761 227,154
Donations 912,910
Other 268,860 3,644
total 16,156,760 19,621,275
*	Includes	Amgen,	Abbott	Laboratories,	Arcagy-Gineco,	Aventis	Pharma,	Bristol-Myers	Squibb,	Fournier	Pharma,	Merck	Serono,	Merck	Sharp	&	
Dohme,	Norvatis,	Pfizer,	Roche,	Sanofi,	Schering	Plough,	Solvay
Funding
Pictured	(left	to	right):	mark	Chatfield,	angus	mcdonald	and	sandra	Healey,	and	nina	stromqvist
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Our	capacity	to	conduct	high-quality	clinical	trials	has	grown	through	expansion	in	our	infrastructure	and	
consequent	strengthening	and	streamlining	of	processes	for	conducting	trials.	Consolidation	of	resources	
of	multiple	collaborative	clinical	groups	through	the	CTC	leads	to	economies	and	ensures	a	critical	mass	
in	specialised	areas	of	expertise.	This	has	helped	our	clinical	trials	program	to	grow	in	breadth	and	depth,	
particularly	in	oncology.	Two	new	collaborative	groups	—	COGNO	(neuro-oncology)	(p.	17)	and	PC4	
(primary	care)	(p.	19)	—	have	started	to	work	with	the	support	of	the	CTC.	
We	are	doing	more	multimodal	studies,	including	trials	of	chemotherapy	with	biologicals	in	addition	to	
radiotherapy	and,	or,	surgery.	Recent	examples	are	TOPGEAR,	ALaCaRT,	and	SUPER	(p.	44),	which	have	
brought	additional	challenges	to	the	program.	Where	possible,	trials	include	consent	for	tissue	analysis,		
so	that	molecular	and	genetic	studies	can	be	an	integral	part	of	the	trials	(p.41).	
Much	of	this	new	work	has	been	underpinned	by	repeated	successful	infrastructure	grants	from	Cancer	
Australia	and	the	Cancer	Institute	of	NSW.	The	CTC,	with	the	oncology	collaborative	groups,	was	awarded	
three	Cancer	Institute	infrastructure	grants,	one	which	is	supporting	central	generic	processes	and	systems,	
specifically	in	the	areas	of	data	systems,	biostatistics	and	quality	assurance.	Two	other	grants	support	
infrastructure	positions	for	each	of	our	collaborative	groups.	
The	Clinical	Trials	Development	Unit,	supported	by	a	grant	from	Cancer	Australia	to	the	CTC	and	the	Centre	
for	Biostatistics	and	Clinical	Trials	at	Peter	MacCallum	Cancer	Centre,	was	an	initiative	to	move	towards	
formally	standardising	the	conduct	of	oncology	studies	in	Australia	and	New	Zealand.	
The	neonatal	program	is	also	expanding,	with	the	aid	of	an	NHMRC	grant	for	the	Australian	Placental	
Transfusion	Study	(p.	22).	In	cardiovascular	disease,	ASPIRE	(p.	26)	is	expanding	internationally.	The	CTC’s	
two	largest	and	longest	trials,	LIPID	(p.	26)	and	FIELD	(p.24),	are	still	in	long-term	follow-up.	Important	
clinical	and	biomarker	substudies	for	both	trials	are	in	preparation	or	publication.
tHE	cLInIcAL	trIALS	
progrAm
“Much of our growth and new work 
has been underpinned by successful 
infrastructure grants .”
Wendy Hague, clinical trials program director
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The	oncology	group	at	the	CTC	specialises	in	running	phase	II	and	phase	III	
investigator-initiated	trials,	from	concept	development	to	final	manuscript	
preparation	and	every	step	in	between.	The	CTC	has	worked	with	over	100	
clinical	sites	across	Australia	and	New	Zealand	as	well	as	in	Singapore,	Canada,	
Taiwan	and	the	UK	to	conduct	trials	to	improve	outcomes	for	cancer	patients.
The	trials	are	run	in	partnership	with	specialised	collaborative	groups.	Five	
well-established	groups	operate	through	the	CTC:
•	 Australasian	Gastro-Intestinal	Trials	Group	(agitg)
•	 Australia	New	Zealand	Gynaecological	Oncology	Group	(anzgog)
•	 Australasian	Lung	Trials	Group	(altg)
•	 Australian	and	New	Zealand	Urogenital	and	Prostate	Cancer	Trials	Group	
(anzup),	formed	from	a	merger	in	2008	of	the	Australian	and	New	Zealand	
Germ	Cell	Trials	Group	and	the	Australian	Prostate	and	Urogenital	Cancer	
Group
•	 Cooperative	Trials	Group	for	Neuro-Oncology	(cogno).
The	CTC	also	works	closely	with:
•	 Australian	New	Zealand	Breast	Cancer	Trials	Group	(anz	bctg),	as	the	
central	randomisation	and	statistical	centre
•	 Primary	Care	Cooperative	Cancer	Clinical	Trials	Group	(PC4),	a	diverse	group	
initiating	trials	requiring	innovative	methods	of	design	and	operation.
These	Australian	groups,	in	turn,	are	associated	with	large	international	
cancer	collaborations,	so	the	CTC	remains	at	the	heart	of	research	initiatives	
throughout	the	world.
In	2008–2009,	14	trials	were	actively	recruiting	and	several	trials	reached	
important	milestones,	including	activation,	final	analysis,	presentation	and	
reporting.
The	oncology	group	of	45	staff,	led	by	the	program	manager	and	the	
team	of	associate	program	managers,	have	maintained	the	CTC’s	reputation	
for	initiation,	concept	development,	coordination,	medical	support,	timely	
completion,	analysis	and	reporting	of	high-quality	trials.
oncology	trials
breast	CanCer
AnZ	Bctg
SnAc
gastrointestinal	CanCer
AgItg	
gynaeCologiCal	CanCer	
AnZgog	
genitourinary	CanCer
AnZup
brain	CanCer
cogno
lung	CanCer
ALtg
Primary	Care
PC4
ImproVIng	QuALIty	oF	LIFE	And	SurVIVAL	In	cAncEr
at	right:	martin	stockler,	oncology	co-director	and	oncology	managers
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Breast	cancer
Australian	new	Zealand	Breast	cancer	trials	group
The	CTC	is	randomisation	and	statistical	centre	for	the	Australian	New	Zealand	
Breast	Cancer	Trials	Group	(anz	bctg).
The	group’s	breast	cancer	trials	are	coordinated	at	the	operations	office	
based	in	Newcastle.	The	CTC	registers	and	randomises	the	trial	patients	and	
also	undertakes	statistical	and	other	analyses	of	trial	data.	The	anz	bctg	has	
13	studies	open	to	recruitment;	the	CTC	randomised	886	patients	during	
2008–2009.
www.anzbctg.org
SnAc	2:	multicentre	trial	of	sentinel	node	biopsy	for	early	
breast	cancer
Before	the	Snac	trial,	women	with	early	breast	cancer	routinely	had	axillary	
clearance	(removal	of	armpit	lymph	nodes)	to	assess	the	spread	of	their	disease.	
The	first-year	follow-up	of	Snac	patients	published	in	2009	showed	that	in	
women	with	tumours	smaller	than	3	cm,	sentinel	node	biopsy	of	selected	
lymph	nodes	could	identify	axillary	tumours	and	had	fewer	side-effects	(such	as	
lymphoedema).
In	Snac	2,	the	investigators	are	continuing	this	research	by	recruiting	
women	with	large	and	multiple	tumours	as	well.	The	aim	is	to	determine	
whether	the	risk	of	recurrence	is	greater	with	the	less	invasive	operation	in	
various	subgroups	of	women.	If	so,	sentinel	node	biopsy	will	become	standard	
practice	for	all	women	with	early	breast	cancer.
AdvAnced cAncer studies: ‘How long HAve i got?’
dr	Kiely	is	a	medical	oncologist	investigating	how	to	estimate	survival	duration	
in	patients	with	various	types	of	incurable	cancer	and	how	clinicians	can	
communicate	this	information	to	patients.	In	her	initial	work,	she	has	reviewed	
data	on	chemotherapy	for	metastatic	breast	cancer	that	would	help	clinicians	
estimate	and	describe	prognosis	for	their	patients	in	this	situation.	She	and	her	
colleagues	have	determined	a	distribution	of	survival	that	can	be	used	to	show	
typical,	best	and	worst	case	scenarios	for	women	starting	chemotherapy.	one	aim	
of	this	work	is	to	help	clinical	oncologists	convey	realistic	hope	when	discussing	
life	expectancy	with	patients	with	advanced	cancer.
these	studies	will	extend	the	value	of	data	obtained	from	the	ctc’s	oncology	trials	
to	provide	new	information	and	prognosis	tools	for	practising	clinicians.
Belinda	Kiely	was	awarded	a	national	Breast	cancer	Foundation	doctoral	
fellowship	for	her	studies	in	advanced	cancer.
belinda	kiely
karen	bracken,	associate	
oncology	program	manager		
for	anz	bctg
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‘For	an	associate	oncology	program	
manager	at	the	ctc,	no	two	days	
are	alike.	At	one	moment	I	am	
working	with	leading	Australian	
researchers	developing	new	studies	
which	could	potentially	change	
the	standard	of	care	for	a	particular	
disease	and	the	next	I’m	involved	
in	coordinating	and	managing	the	
talents	of	our	clinical	trials	team,	
pointing	them	towards	a	common	
goal.	due	to	the	sheer	length	of	
our	trials,	seeing	a	project	through	
from	its	infancy	to	completion	is	a	
rare	feat.	However,	being	involved	
in	the	daily	challenges	allows	us	to	
use	our	diverse	range	of	skills	and	
knowledge	leading	to	achievement	
of	our	professional	goals.’
—	reena	gill,	associate	oncology	
program	manager	for	the	
Australasian	gastro-Intestinal	trials	
group
MAX study—A low-toXicity regiMen  
for colorectAl cAncer
Analysis	of	the	mAX	study	data	was	completed.	the	results	showed	
that	adding	bevacizumab,	with	or	without	mitomycin,	to	capecitabine	
significantly	improves	progression-free	survival	without	causing	major	
additional	toxicity	or	impairment	of	quality	of	life.	this	new	low-toxicity	
regimen	may	be	a	treatment	option	for	patients	with	metastatic	colorectal	
cancer,	especially	older	patients.
the	results	of	mAX	were	presented	at	the	meeting	of	the	American	Society	
of	clinical	oncology	and	at	the	European	multidisciplinary	cancer	congress	
in	2009.
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gastrointestinal	cancer	trials
The	CTC	coordinates	the	trials	of	the	Australasian	Gastro-Intestinal	Trials	Group	
(agitg),	the	Australian	collaborative	group	for	research	into	gastrointestinal	
cancers	(which	can	occur	in	the	oesphagus,	stomach,	liver,	gall	bladder,	pancreas	
or	bowel).	
The	CTC	works	closely	with	agitg	clinicians	and:
•	 provides	project	management,	trial	coordination,	quality	assurance,	trial	
design,	biostatistical	analysis	and	data	management
•	 supports	new	trials,	including	multidisciplinary	trials	in	surgery,	radiotherapy,	
chemotherapy,	translational	research	and	supportive	care
•	 educates	and	trains	new	investigators	and	research	fellows	in	trial	methods	
and	protocol	development
Throughout	2009,	the	CTC	managed	and	coordinated	25	trials	in	
gastrointestinal	cancer,	some	in	the	final	stages	of	development,	some	actively	
recruiting	and	some	in	follow-up.	
Over	2700	patients	have	now	been	recruited	to	38	agitg	trials,	and	the	
group	has	75	sites	in	Australia,	New	Zealand,	Singapore,	Hong	Kong	and	the	
United	Kingdom.	In	2008–2009,	five	trials	were	open	to	recruitment	—co20,	
quaSar2,	deco,	regiSter	and	petacc	6.	Da	Vinci,	eSpac3	and	Adjuvant	giSt	
closed	during	2009,	and	another	7	trials	were	in	active	follow-up.	
www.gicancer.org.au
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Hani	adhami,	ilka	kolodziej,	
Julie	martyn,	ayanthi	salgado	
(executive	officer	of	anzgog)	
and	sarah	Chinchen
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gynaecological	cancer
The	CTC	coordinates	all	the	trials	
of	the	Australia	New	Zealand	
Gynaecological	Oncology	Group	
(anzgog),	which	was	established	
in	2002	and	incorporated	in	
2009.	anzgog	collaborates	with	
international	study	groups	through	
membership	of	the	Gynecologic	
Cancer	Intergroup	(gcig).	The	
associate	oncology	program	
manager	for	the	anzgog	trials,	
Julie	Martyn,	recently	became	chair	
of	its	Harmonisation	and	Statistics	
Committee.
anzgog	has	recruited	over	500	
patients	from	47	clinical	sites	in	
Australia	and	New	Zealand.	Currently,	
three	are	open	to	recruitment:	
portec	3,	ovar	16	and	Symptom	Benefit.	icon	6	(stage	2)	and	Outback	are	
pending.	Another	six	trials,	in	ovarian	cancer,	have	closed	to	recruitment,	and	
their	patients	are	being	followed	up.	
The	CTC	is	statistical	centre	for	the	large	international	Calypso	trial.	This	
ovarian	cancer	trial	showed	that	combination	treatment	with	carboplatin	and	
pegylated	liposomal	doxorubicin	led	to	longer	progression-free	survival	than	
standard	chemotherapy	in	patients	with	platinum-sensitive	recurrent	ovarian	
cancer.	The	results	were	presented	at	the	meeting	of	the	American	Society	
of	Clinical	Oncology,	the	European	Society	of	Gynecological	Oncology	and	
the	European	Society	for	Medical	Oncology	in	2009.	Patients	continue	to	be	
followed	up,	and	work	on	secondary	analyses	is	continuing.
www.anzgog.org.au
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AnZuP is off  
to A good stArt
In	2009, anzup	continued	to	
recruit	patients	to	five	trials	and	
activated	another	—	raves,	in	
collaboration	with	the	trans-
tasmanian	oncology	group.
‘the	associate	oncology	program	
manager’s	role	for	anzup	at	
the	ctc	has	provided	me	with	
opportunities	to	mentor	more	
junior	staff,	liaise	with	experts	in	
the	field,	and	gain	exposure	to	all	
aspects	of	project	management	
from	concept	development	to	
close-out.	the	opportunities	
offered	by	ctc	are	diverse,	and	
both	personally	and	professionally	
rewarding.’
—	amy	boland,	associate	
oncology	program	manager	for	
the	Australian	and	new	Zealand	
urogenital	and	prostate	cancer	
trials	group
genitourinary	cancer	trials
In	2008,	the	Australian	and	New	Zealand	Germ	Cell	Trials	Group	
(anzgctg)	and	Australian	Prostate	and	Urogenital	Cancer	Group	(apug)	
amalgamated	to	form	the	new	collaborative	group,	the	Australian	and	
New	Zealand	Urogenital	and	Prostate	Cancer	Trials	Group	(anzup).	anzup	
is	supported	by	funding	from	Cancer	Australia	under	its	Support	for	Cancer	
Clinical	Trials	program.
Sorce,	an	international	trial	initiated	in	the	UK	and	Europe,	is	the	first	
anzup	trial	in	renal	cell	cancer,	and	began	in	Australia	in	2009.	Australian	
investigators,	Martin	Stockler	and	Prunella	Blinman,	have	also	designed	
and	developed	a	substudy	on	patient	preferences	(page	18),
Accelerated	BEP,	a	feasibility	study	of	an	accelerated	chemotherapy	
regimen	for	advanced	germ-cell	tumours,	continues	to	recruit	patients.	
Encouraging	results	from	this	trial	and	a	similar	UK	trial	have	provided	
the	rationale	for	a	full-scale	randomised	trial	of	the	regimen.	Chemo	
&	Cognition	is	a	national	longitudinal	study	of	learning,	memory	and	
attention	after	chemotherapy	for	testicular	cancer.	The	study	will	have	
implications	for	informed	consent	and	the	way	future	clinical	trials	are	
investigated,	and	is	especially	important	with	cancer	survivors	living	longer.	
Another	trial	is	seeking	to	establish	the	value	of	an	aprepitant-containing	
anti-emetic	regimen	in	preventing	chemotherapy-induced	nausea	and	
vomiting	for	patients	receiving	5-day	cisplatin-based	chemotherapy.
Eligible	patients	can	enrol	in	all	three	trials:	Accelerated	BEP,	Aprepitant	
and	Chemo	&	Cognition.
www.anzup.org.au
Brain	cancer	trials
The	Cooperative	trials	Group	for	Neuro-Oncology	(cogno)	is	a	national	
collaborative	trials	group	formed	in	late	2007	with	funding	from	Cancer	
Australia.	
The	CTC	is	the	coordinating	centre	for	the	group	and	is	currently	
completing	data	management	for	a	phase	II	trial	of	the	combination	of	
temozolomide	and	liposomal	doxorubicin	for	glioblastoma	multiforme,	a	
brain	cancer.
The	group	has	also	joined	with	the	European	Organisation	for	Research	
and	Treatment	of	Cancer	(eortc)	to	conduct	the	catnon	trial	in	Australia.	
The	trial	is	investigating	chemotherapy	treatment	added	to	radiotherapy	
for	glioma.	cogno	held	its	first	scientific	meeting	in	2008	and	discussed	
three	new	local	concepts	for	trials	to	add	to	those	already	running	and	two	
being	prepared	for	start-up.
www.cogno.org.au
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individuAl PAtient Preferences is A MAjor strAnd of 
tHe ctc’s oncology reseArcH
dr	Blinman	is	undertaking	studies	on	the	preferences	of	patients	and	their	
doctors	for	chemotherapy	treatment.	the	studies	use	the	methods	of	Simes	and	
coatesto	determine	how	patients	and	doctors	trade	off	the	benefits	and	harms	of	
chemotherapy.	
In	a	recently	published	study,	she	found	that	very	small	survival	benefits	made	
adjuvant	chemotherapy	for	early	colon	cancer	worthwhile,	but	preferences	were	
highly	variable	and	not	readily	predictable.
dr	Blinman	received	a	young	Investigator	Award	from	the	ASco	cancer	
Foundation	in	the	united	States	for	her	work	on	preferences	for	adjuvant	
chemotherapy	in	non-small-cell	lung	cancer.	She	presented	results	at	national	and	
international	meetings	in	2009,	and	this	work	is	continuing.	
other	preferences	studies	include	one	determining	preferences	for	adjuvant	
sorafenib	in	resected	renal	cell	cancer.	this	is	a	longitudinal	preference	study	
developed,	coordinated	and	led	by	the	ctc	as	part	of	the	international	phase	III	
sorce	trial	(page	46).
Prunella	blinman
PHd
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An	initiative	to	close	the	evidence	
gaps	in	oncology	in	primary	care
In	mid-2009	the	CTC	began	collaborating	with	the	
Primary	Care	Cooperative	Cancer	Clinical	Trials	Group	
(PC4),	the	newest	national	cooperative	oncology	group	
funded	by	Cancer	Australia.
The	group	focuses	on	prevention	and	detection	of	
cancer	and	care	of	people	with	cancer	and	currently	
unanswered	research	questions	in	these	areas.	It	is	actively	
working	to	develop	and	conduct	large-scale	multisite	
studies	and	build	research	infrastructure	in	primary	care.
The	CTC	has	representation	on	executive	and	advisory	
committees,	and	its	particular	roles	are	trials	development	
support,	with	advice	and	expertise	in	trial	operations,	
statistics	and	clinical	epidemiology.	In	2009,	the	CTC	
worked	with	the	group	to	run	two	concept-development	
workshops,	where	participants	had	an	opportunity	to	
workshop	their	ideas	for	new	clinical	trials.
A	new	approach	to	trials	research	in	primary	care	is	
needed.	It	has	special	challenges,	including	the	diversity	of	
general	practice	patients	and	the	complexity	of	their	care,	
and	the	variety	of	health	professionals	involved.
www.pc4tg.com.au
Lung	cancer	trials
The	CTC	coordinates	the	trials	of	the	Australasian	Lung	
Cancer	Trials	Group	(altg),	which	aims	to	reduce	the	
incidence	and	related	mortality	and	morbidity	of	lung	and	
thoracic	cancers	and	improve	the	quality	of	life	of	patients	
with	lung	cancer.	The	group	is	supported	by	infrastructure	
grants	from	Cancer	Australia.
Four	trials	have	been	developed:	mateS,	nitro,	pact	
in	non-small-cell	lung	cancer,	and	BR.29.	mateS,	a	study	
of	thalidomide	for	mesothelioma,	is	a	collaboration	with	
a	Dutch	group,	and	BR.29	is	a	collaboration	with	the	
National	Cancer	Institute	of	Canada	Clinical	Trials	Group	
(ncic	ctg).	A	trial	using	a	novel	vascular	disrupting	agent	
for	mesothelioma	is	being	developed.
‘Preferences	for	adjuvant	chemotherapy	in	non-small-
cell	lung	cancer:	what	makes	it	worthwhile	to	patients	and	
their	doctors?’	is	a	multicentre	observational	cohort	study	
of	preferences	for	adjuvant	chemotherapy	for	patients	
undergoing	surgery	for	lung	cancer.	Results	for	patients’	
preferences	were	presented	at	the	World	Conference	on	
Lung	Cancer	in	2009	by	CTC	research	fellow,	Prunella	
Blinman.	
www.altg.com.au
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neonatal	trials
The	CTC	started	its	first	neonatal	trial	in	2001	as	part	of	its	aim	of	conducting	
trials	in	areas	of	need.	The	trial,	iniS,	now	approaches	completion	after	enrolling	
over	3400	infants	internationally.
Other	large	trials	are	being	conducted	or	developed	—	such	as	booSt	ii,	
which	will	soon	reach	full	recruitment,	and	APTS,	which	began	as	a	pilot	study	
in	2009.	These	trials	also	contribute	to	worldwide	meta-analyses	of	data	from	
many	thousands	of	patients.	The	CTC	has	participated	or	taken	a	lead	in	setting	
up	networks	of	investigators	who	are	making	this	happen.
what	level	of	oxygen	is	right	for	premature	babies?
The	CTC’s	booSt	ii	trial	(Benefits	of	Oxygen	Saturation	Targeting)	is	one	of	
several	large	trials	around	the	world	aiming	to	ascertain	which	of	two	ranges	
of	oxygen	saturation	within	the	current	clinical	range	used	is	better	for	very	
premature	babies.
inis
boost	ii
aPts
“Trials to achieve healthy 
outcomes for extremely 
premature babies are 
challenging. We work with 
clinicians through global 
partnerships, aiming to find 
cost-effective treatments that 
will reduce death and illness 
among infants.” 
A	BEttEr	LIFE	For	nEwBornS
lucille	sebastian,	inis	manager,	and	alpana	ghadge,	boost	ii	manager.
Too	little	oxygen	for	long	periods	may	harm	brain	cells	and	
contribute	to	chronic	lung	disease	or	increase	the	risk	of	death.	Too	
much	oxygen	for	long	periods	is	known	to	cause	damage	to	the	
eyes,	may	impair	brain	development	or	lung	development,	and	may	
also	increase	the	risk	of	death.
Infants	are	randomised	to	either	85–89%	oxygen	saturation	
target	or	to	91–95%	oxygen	saturation	target.	Oxygen	saturation	
is	measured	with	adjusted,	masked	Masimo	Radical	SET	pulse	
oximeters.	The	oxygen	saturation	monitoring	for	the	study	
continues	until	the	infant	reaches	a	corrected	gestational	age	of	36	
weeks	or	consistently	breathes	in	room	air.
Of	the	1036	infants	enrolled,	218	have	been	followed	up	for	their	outcomes	
at	2	years,	corrected	for	gestation.
The	abnormalities	being	measured	are	rare,	so	even	1200	infants	in	the	trial	
will	not	be	enough	to	determine	a	clear	difference	between	the	two	oxygen	
targets.	The	data	from	the	trial	are	being	combined	with	data	from	five	other	
similar	trials	in	other	countries	in	the	international	Neonatal	Oxygenation	
Prospective	Meta-analysis	(NeOProM)	(page	32).	Eventually,	data	from	5200	
infants	will	be	available	for	a	meta-analysis	that	was	planned	before	the	trials	
began.
a
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Immunoglobulin	for	infection
The	International	Neonatal	Immunotherapy	Study	(iniS)	is	evaluating	
polyclonal	immunoglobulin	(IVIG)	added	to	antibiotic	therapy	for	newborn	
infants	with	serious	infection.	Infants	were	recruited	from	Australia,	New	
Zealand,	United	Kingdom,	Europe	and	Argentina.
Infants	with	low	birth	weight	and	suspected	serious	infection	received	
infusions	of	IVIG	(Intragam	P)	or	placebo.	The	main	outcome	being	measured	
is	survival	without	major	disability	at	2	years,	corrected	for	gestational	age.	iniS	
finished	recruitment	in	May	2007	in	Australia	and	New	Zealand.	The	cohort	of	
1398	babies	from	Australia	and	New	Zealand	was	40%	of	the	global	total	of	
3493.	Locally,	the	trial	successfully	followed	up	97%	of	babies	eligible	to	answer	
the	primary	study	question.
does	placental	blood	help	premature	babies?
Researchers	led	by	Professor	William	Tarnow-Mordi	are	investigating	the	value	
of	a	simple	technique	to	improve	the	health	and	survival	of	infants	born	more	
than	10	weeks	early.	These	infants	have	a	higher	rate	of	death	and	disability	than	
babies	born	at	term.
Placental	transfusion	can	deliver	as	much	as	30	more	millilitres	of	blood	
to	the	baby.	It	is	done	by	one	of	three	methods:	cord	milking,	delayed	cord	
clamping,	or	a	combination	of	both.	The	method	leading	to	the	highest	
haemoglobin	levels	will	be	the	intervention	arm	in	the	main	trial.	Recruitment	
began	in	2009	for	the	pilot	study.
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“Amputation is a real  
threat for diabetes patients. 
Fenofibrate treatment  
appears to substantially  
reduce this risk”
Anthony Keech, deputy director
prEVEntIng		
cArdIoVAScuLAr	
dISEASE
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field
asPire
liPid
the	international field	trial:	results	continue	to	
reveal	benefits	of	treatment	for	diabetes
The	field	(Fenofibrate	Intervention	and	Event	Lowering	in	Diabetes)	trial	
is	a	study	of	using	fenofibrate	to	modify	blood	lipids	and	therefore	reduce	
cardiovascular	disease	in	people	with	type	2	diabetes.
The	main	results	were	published	in	2005,	but	subsidiary	analyses	looking	
at	secondary	and	tertiary	endpoints	planned	in	the	trial	protocol	are	still	
continuing.	One	study	showed	that	fenofibrate	reduced	the	risk	of	amputation	
of	the	toes	by	almost	half.	Another	explored	various	features	of	the	metabolic	
syndrome:	people	with	very	high	triglyceride	levels	had	the	highest	risk	and	also	
the	greatest	benefit	from	fenofibrate	treatment.
Many	patients	in	field	started	using	statin	drugs	during	the	5	years	of	the	
trial,	confounding	the	main	results.	The	investigators	therefore	developed	a	
new	method	for	adjusting	the	effects	of	a	study	drug	for	other	treatments	taken	
up	during	a	trial.	This	was	presented	at	the	meeting	of	the	American	Heart	
Association.
cardiovascular	trials
diAbetic MicrovAsculAr diseAse
dr	ting	is	looking	at	the	safety	of	fenofibrate	and	its	effects	on	diabetic	kidney	
disease.	the	well-known	acute	rise	in	serum	creatinine	with	fenofibrate	has	
been	found	to	be	completely	reversible	even	after	5	years	of	treatment.	Hence,	
the	creatinine	rise	may	not	indicate	structural	damage	to	the	kidney;	in	fact,	the	
preservation	of	renal	function	is	unmasked	on	drug	withdrawal.
part	of	the	project	examines	risk	predictors	of	diabetic	microvascular	disease,	with	
emphasis	on	renal	pathology.	the	loss	of	glomerular	filtration	and	albumin	leak	
appear	to	represent	two	separate	pathological	processes	with	different	sets	of	risk	
factors.
complementary	basic	science	experiments	investigate	the	mechanism	of	action	of	
fenofibrate.	mesangial,	podocyte	and	proximal	tubule	cell	cultures	will	be	exposed	
to	a	diabetic	milieu,	and	the	effects	of	fenofibric	acid	on	the	pathological	changes	
of	diabetic	nephropathy	examined:	for	example,	upregulation	of	collagen.	
Animal	experiments	will	be	conducted	to	validate	these	findings,	and ppar-alpha	
knockout	mice	will	be	used	to	find	out	whether	the	renal	effects	of	fenofibrate	are	
solely	ppar	-mediated	or	not.
ru-dee	ting,	cardiology	fellow
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lAborAtory And clinicAl vAsculAr studies
dr	rajamani	is	using	cell,	molecular,	and	animal	models	and	human	clinical	
studies	to	determine	the	mechanisms	of	blood	vessel	damage	and	repair	in	
patients	with	type	2	diabetes.	these	studies	are	extending	the	results	of	the	
field	trial.	the	objective	is	to	identify	novel	mechanisms	of	vascular	injury	
in	diabetes	and	potential	pathways	through	which	the	clinical	benefits	of	
fenofibrate	are	mediated	—	at	genetic,	cellular	and	molecular	levels.
In	2009,	dr	rajamani	took	a	major	role	in	the	field	amputation	study,	
published	in	The Lancet.	current	research	includes:
•	 using	clinical	and	biochemical	variables	to	predict	the	risk	of	an	amputation
•	 laboratory	studies	of	the	effects	of	hyperglycaemia	on	migration,	
proliferation,	tubulogenesis	and	apoptosis	of	cultured	human	vascular	
endothelial	cells
•	 simulation	of	limb	ischaemia,	wound	
healing	and	the	effects	of	fenofibrate	in	
mice
•	 finding	specific	genetic	biomarkers	of	
vascular	injury	in	diabetes	patients.
field AMPutAtion study
An	amputation	due	to	diabetes	
occurs	around	every	30	seconds	
somewhere	in	the	world.	
In	field,	fenofibrate	treatment	was	
found	to	reduce	the	risk	of	a	first	
diabetes-related	amputation	by	
36%.	this	important	finding	was	
reported	in	The Lancet	in	may	2009.	
the	risk	of	a	minor	amputation	
(toes)	without	known	large-vessel	
disease	was	47%	lower	in	the	
fenofibrate	group.
A	patient’s	height	was	a	major	
predictor	of	amputations.	the	risk	
of	an	amputation	increased	by	
60%	for	every	10	centimetres	of	a	
patient’s	height.
Amputation	is	a	real	threat	for	
diabetes	patients,	even	when	their	
blood	glucose	and	blood	pressure	
are	kept	under	control,	and	is	
dramatically	higher	for	those	who	
have	already	had	skin	ulceration	or	
amputation.	Fenofibrate	treatment	
appears	to	substantially	reduce	
this	risk. 
kushwin	rajamani,		
cardiology	fellow
Over	a	million	Australians	have	diabetes.	The	costs	of	diabetes	were	
estimated	by	the	Diabcost	survey	in	2002	at	$3	billion	a	year,	and	diabetes	is	
implicated	in	8%	of	deaths	in	Australia.	Therefore,	the	research	by	the	field	
investigators	has	important	financial	implications,	especially	with	the	increased	
cost	of	health	care	and	the	aging	population.
The	next	major	phase	of	the	field	trial	is	laboratory	analysis	of	patients’	
blood	samples.	This	will	allow	the	investigators	to	determine	biological	and	
genetic	markers	of	risk.	field	is	also	continuing	with	long-term	follow-up.	Of	
about	8000	patients	in	Australia	and	New	Zealand,	about	16%	have	died	and	
the	rest	are	being	followed	up	by	questionnaire	or	registry	search	to	ascertain	
their	outcomes.
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A	large	cost-efficient	trial:	aspire
Several	million	patients	worldwide	who	have	had	a	venous	thromboembolism	
are	at	risk	of	another.
The	aim	of	aSpire	is	to	determine	whether	low-dose	aspirin	prevents	
recurrence	of	thromboembolism.	aSpire	is	also	examining	the	safety	of	
long-term	aspirin	in	these	patients,	exploring	risk	factors	for	recurrent	
thromboembolism,	exploring	the	link	between	venous	and	arterial	thrombosis,	
and	assessing	the	cost-effectiveness	of	aspirin	therapy.
aSpire	began	in	Australia	and	New	Zealand	in	2004.	A	larger	patient	base	
was	sought	by	expanding	into	Singapore,	the	United	Kingdom,	more	recently,	
India	and,	in	the	future,	Argentina.	Over	650	patients	have	been	recruited.
Italy	has	a	very	similar	trial	(warfaSa).	The	aSpire	and	warfaSa	
investigators	are	cooperating	in	the	inSpire	prospective	meta-analysis,	led	by	
the	Australian	investigators.
Long-term	effects	of		
cholesterol-lowering	therapy:	lipid
Patients	in	the	Long-Term	Intervention	with	Pravastatin	in	Ischaemic	Disease	
(lipid)	trial	were	recruited	between	1990	and	1992	and	had	clinical	follow-
up	for	an	average	of	six	years.	The	results	of	the	trial	were	published	in	1998.	
Over	90%	of	surviving	patients	are	still	being	being	followed	up	by	letter	
and	telephone,	and	other	data	come	from	searches	of	registers	of	morbidity,	
mortality	and	cancer.	The	information	is	being	used	to	assess	the	long-term	
safety	and	cost-effectiveness	of	pravastatin	treatment,	a	project	funded	by	the	
nhmrc.
Blood	samples	collected	over	the	first	six	years	of	the	trial	are	being	analysed	
in	the	laboratories	of	collaborating	scientists	from	Germany,	Sweden	and	the	
United	States,	and	will	soon	be	used	in	a	new	round	of	investigations	of	how	
various	blood	components	are	related	to,	first,	the	risk	of	disease	and,	second,	
the	effects	of	pravastatin.
Recent	publications	resulting	from	lipid	data	include:	biostatistical	studies	
analysing	the	risk	of	a	recurrent	cardiovascular	event;	a	study	showing	that	two	
major	biomarkers	were	associated	with	future	coronary	heart	disease;	a	study	
describing	differences	in	Australian	and	New	Zealand	cardiovascular	mortality	
according	to	socioeconomic	status;	and	an	investigation	of	optimal	intervals	for	
cholesterol	monitoring.
rebecca	mister,		
project	manager	for	aspire
	 NHMRC	CLINICAL	TRIALS	CENTRE:	2008–2009	RESEARCH	REPORT	 27
Prev
en
tin
g
	Ca
rd
io
va
sCu
la
r	d
isea
se
coronary	heart	disease	biomarkers
The	lipid	study	continues	to	provide	information	about	the	ongoing	
risks	of	patients	who	have	had	coronary	heart	disease.	One	study	showed	
that	two	biomarkers	predicted	the	risk	of	future	cardiovascular	events	
(with	odds	of	more	than	1)	and	two	others	did	not.	The	analyses	were	
adjusted	for	confounders	(including	age,	prior	myocardial	infarction,	
diabetes,	and	prior	stroke).
Helen	Pater,	project	manager	for	lipid
NT-proBNP
TIMP-1
C-reactive protein
Interleukin-6
0 1 2 3 4 5 6 7
Odds ratio with 95% CI
Biomarker
Biostatistics
Biostatistics	has	a	central	role	in	trials	from	initiation	and	design	through	to	
the	final	report.	CTC	biostatisticians	have	responsibility	as	the	statisticians	for	
national	and	international	trial	groups	undertaking	research	into	cardiovascular	
disease,	diabetes,	neonatal	intensive	care,	and	breast,	gastrointestinal,	
gynaecological,	urogenital	and	brain	cancers.	They	also	participate	in	
independent	safety	data	monitoring	committees,	which	oversee	trial	safety	at	
arm’s	length	from	the	study	investigators.
As	part	of	a	new	collaboration	with	the	Menzies	Research	Institute	in	
Darwin,	in	2008	and	2009	statisticians	presented	workshops	covering	material	
from	design	of	trials	to	advanced	statistical	methods	for	analysis	of	trial	
data.	Researchers	had	the	opportunity	to	present	a	study	plan	for	discussion	
and	development.	This	activity	has	paved	the	way	for	collaborative	trials	in	
Aboriginal	health.	The	first	of	these,	abracadabra,	is	a	multisite	trial	to	assess	
a	web-based	early	literacy	program.	School	absenteeism	has	presented	special	
challenges.	The	success	of	the	intervention	will	be	measured	by	improvements	
in	students’	phonological	awareness	and	word	reading.	Other	outcomes	to	be	
assessed	include	early	literacy	skills,	phoneme–grapheme	correspondence	and	
mathematics.	Poor	literacy	underpins	many	health	problems	in	indigenous	
groups,	so	an	improvement	in	early	literacy	can	potentially	improve	health	in	
the	future.
biostatistiCs
CtC	outreaCH	Program
biostatistiCs	Collaboration		
of	australia
eduCation
stAtisticAl MetHods And issues in AnAlysis of HeAltH-
relAted trAde-offs
overall	summary	measures	are	often	needed	in	clinical	trials	that	evaluate	
quality	of	life,	in	order	to	encapsulate	the	balance	of	positive	and	negative	
impacts	of	conditions	and	treatments	on	different	quality-of-life	dimensions	
and	on	other	outcomes	such	as	health	status	and	survival.
In	this	project,	dr	Annette	Kifley	and	colleagues	are	developing	joint	models	
for	multidimensional,	mixed	outcomes	in	quality-of-life	trials	by	applying	
and	extending	latent	variable	modelling	methods.	the	work	will	be	useful	
for	pharmacoeconomic	assessments	and	individual	clinical	decision	making	
about	the	overall	value	of	different	therapeutic	strategies.
ImproVIng	AnALySIS	And	conduct	oF	cLInIcAL	trIALS
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“Biostatistics plays a pivitol role in underpinning the science  
of clinical trial designs as well as ensuring the study results  
are correctly interpreted.”
Val Gebski, director, Biostatistics.
develoPing A new 
clinicAl triAl:  
tHe stAtisticiAn’s view
‘In	the	mel-d	study,	a	phase	II	pilot	
trial	to	assess	the	effectiveness	of	
vitamin	d	in	preventing	melanoma	
recurrence,	the	design	team	has	
included	a	biochemist,	a	surgeon,	
a	clinical	researcher,	a	statistician,	
a	clinical	trials	manager,	a	data	
manager	and	a	clinical	trials	
coordinator.
‘It	has	taken	over	1	year	from	the	
concept	stage	to	getting	the	trial	
up	and	running.	It	will	take	at	least	
another	2	years	before	the	study	
can	answer	its	research	question.
‘my	role	in	the	mel-d	trial	as	a	
biostatistician	is	not	just	about	
“doing	the	stats”.	It’s	about	
problem	solving,	learning	how	to	
communicate	statistical	concepts	
to	the	group,	and	helping	design	
case	report	forms,	among	other	
things.	It	has	been	insightful	and	
rewarding	experience.’
—	diana	Zannino,	biostatistician
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ctc	outreach
CTC	Outreach	is	a	research	support	program	designed	to	promote	high-quality	
clinical	trials	in	currently	unsupported	clinical	areas,	including	surgery,	current	
clinical	practice,	new	health	technologies,	clinical	management,	palliative	and	
supportive	care,	and	complementary	medicine.	Expertise	available	to	new	
investigators	and	groups	includes:
•	 study	design	and	conduct,	including	statistical	considerations,	and	database	
and	forms	design
•	 concept	development,	including	outlines,	trial	proposals,	protocols	and	
funding	applications
•	 randomisation	and	drug	distribution	systems
•	 development	of	clinical	research	skills
•	 establishing	trials	support	networks	in	therapeutic	areas	currently	not		
catered	for.
During	2008–2009,	Outreach	supported	over	60	research	and	education	activities.	Highlights	have	included	collaboration	
on	several	projects	funded	by	the	NHMRC	and	sponsorship	of	training	workshops	and	short	courses	in	trial	concept	
development	and	methods.	The	functionality	of	the	CTC’s	randomisation	and	data	management	systems	have	been	
extended,	so	more	trials	can	be	supported.	Outreach	has	contributed	to	the	development	and	ongoing	success	of	research	
networks	in	kidney	disease,	paediatrics,	neonatal	disorders	and	indigenous	health.
The	program	is	funded	by	the	National	Health	and	Medical	Research	Council	of	Australia.
Biostatistics	collaboration	of	Australia	(BcA)
The	BCA,	a	collaboration	of	seven	universities	administered	at	the	
CTC,	is	meeting	the	workforce	need	for	biostatisticians	in	Australia.	
The	BCA	offers	postgraduate	qualifications	from	each	of	its	member	
universities	and	provides	courses	by	distance	education.	After	10	years	of	
its	operation,	182	have	graduated	(86	master,	33	graduate	diploma,	63	
graduate	certificate)	and	currently	248	students	are	enrolled.
This	achievement	as	a	model	for	collaborative	education	was	reported	
in	a	paper	in	The	American	Statistician:	‘Biostatistics	@	distance:	a	model	
for	successful	multi-institutional	delivery’.
www.bca.edu.au
The	BCA	has	close	ties	with	
the	NSW	Health	Biostatistics	
Training	Program,	which	
is	also	celebrating	its	10th	
anniversary.
BcA	academic	staff,	left	to	right:		
professor	John	carlin	(university	of	
melbourne),	professor	Judy	Simpson	
(university	of	Sydney),	dr	Keith	dear	
(Australian	national	university),		
professor	philip	ryan	(university	of	
Adelaide),	professor	Andrew	Forbes	
(monash	university),	professor	Annette	
dobson	(university	of	Queensland),	
professor	cate	d’Este	(university	of	
newcastle),	professor	gillian	Heller	
(macquarie	university),	and		
ms	Helen	moore	from	nSw	department	
of	Health,	who	supervises	the	nSw	Health	
Biostatistics	training	program.	
andrew	martin,		
senior	biostatistian	for	outreach
www.outreachclinicaltrials.org.au
Education	for	clinical	trials
The	CTC	has	a	program	of	education	activities	designed	to	increase	the	quality	and	number	of	trials	undertaken	in	
Australia	and	improve	the	interpretation	and	implementation	of	their	results.	New	courses	are	continually	being	
developed:
•	 Time-to-event	analysis	is	an	advanced	statistical	technique	accounting	for	the	observation	that	the	clinical	event	
being	measured	may	occur	early	in	some	patients	and	later	in	others;	others	yet	may	die	or	drop	out	of	a	trial	for	
other	medical	reasons	altogether.	The	intense	5-day	course	in	time-to-event	methods	was	first	offered	in	2008.	
Simple	and	complex	analysis	strategies	were	covered,	with	an	emphasis	on	interpreting	results	and	the	advantages	
and	pitfalls	of	different	approaches.	
•	 Equivalence	and	noninferiority	study	designs	are	becoming	increasingly	common,	but	design	and	analysis	methods	
are	still	not	well	understood.	A	course	on	equivalence	designs	and	interim	analysis	was	presented	for	the	first	time	in	
2009.	The	participants	came	from	varied	backgrounds,	mainly	medical,	with	most	having	a	basic	level	of	knowledge.	
Participants	appreciated	the	quality	and	comprehensiveness	of	the	course,	saying	it	was	pitched	at	the	right	level.
•	 The	CTC	with	Professor	James	A	Talcott	from	Harvard	conducted	a	5-day	advanced	clinical	trials	course	under	the	
auspices	of	the	NSW	Office	of	Scientific	and	Medical	Research	and	the	NSW	Cancer	Institute.	Participants	brought	
their	trial	proposals	for	developing	in	practical	sessions.
CTC	biostatistians	and	others	develop	and	deliver	regular	educational	programs,	including:	short	courses	for	clinical	
researchers	and	biostatisticians;	lectures	and	workshops	for	radiation	oncology	trainees;	workshops	on	study	design	
and	data	management	for	paediatrics	at	the	Children’s	Hospital	Westmead;	and	workshops	on	developing	concepts	and	
protocols	for	trials.
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Systematic	reviews	and	meta-analyses
In	systematic	reviews,	information	is	obtained	comprehensively	from	all	possible	
sources	to	obtain	the	best	unbiased	evidence.	The	CTC	undertakes	systematic	
reviews	and	meta-analysis	to	investigate	important	clinical	questions	and	also	to	
assess	new	medical	devices	and	technology.
Prospective	meta-analysis,	in	which	the	data	collection	and	analyses	for	more	
than	one	trial	are	planned	in	concert	before	the	trials	are	conducted,	is	the	gold	
standard	in	medical	research.	It	is	particularly	useful	in	research	areas	where	large	
numbers	of	patients	are	required	for	statistical	analysis.	The	CTC	is	a	leader	in	
prospective	meta-analysis	methods.	
perinatal	meta-analyses
oxygen	tHeraPy	for	neonates
The	Neonatal	Oxygenation	Prospective	Meta-Analysis	(NeOProM)	is	a	current	
collaboration	of	investigators	for	the	CTC’s booSt	II	trial	(page	21)	and	trial	
investigators	in	the	United	States,	United	Kingdom,	New	Zealand	and	Canada,	
who	together	plan	to	recruit	over	5000	infants	born	at	less	than	28	weeks’	
gestation.	This	prospective	meta-analysis	is	expected	to	answer	the	question	of	
the	optimum	level	of	oxygen	for	very	preterm	infants.
nitriC	oxide	in	assisted	ventilation
Preterm	infants	often	require	assisted	ventilation,	which	has	a	risk	of	lung	and	
neurological	injury.	Some	trials	have	shown	that	inhaled	nitric	oxide	reduces	
these	risks.	In	mappino,	individual-patient	data	from	several	trials	are	being	
reanalysed	to	settle	this	question	and	to	identify	any	characteristics	of	the	infants	
that	may	show	benefits	of	inhaled	nitric	oxide.
HigH-frequenCy	osCillatory	assisted	ventilation
Prevention	of	Ventilator-Induced	Lung	injury	in	Preterm	Infants	with	Respiratory	
Distress	Syndrome	(Previlig)	is	a	systematic	review	and	individual-patient-
data	meta-analysis	of	the	value	of	high-frequency	oscillatory	ventilation	
compared	with	conventional	mechanical	ventilation	in	reducing	the	risk	of	
bronchodysplasia	and	consequent	disability	in	preterm	infants.	The	dataset	
includes	3229	participants	in	10	trials.
Combining	evidenCe
SyStEmAtIc	rEVIEwS	
	And	mEtA-AnALySES
cocHrAnE	coLLABorAtIon
evidenCe	for	deCision	making
AnZctr
EVALuAtIng	cLInIcAL	tEStS
mSAc
every	Patient	is	different
rISK	modELS
quality	of	life
translational	researCH
EVIdEncE	For	dEcISIon	mAKIng
combining	trial	evidence
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“The CTC undertakes 
systematic reviews 
and meta-analysis to 
investigate important 
clinical questions and 
to assess new medical 
devices and technology.“
Dr Lisa Askie, director of 
systematic reviews. Lisa 
also has leading roles in 
international neonatal 
collaborations.
antiPlatelets	for	Preventing	Pre-eClamPsia
The	pariS	collaboration	was	the	first	individual-patient-data	analysis	in	the	
perinatal	field.	It	showed	that	use	of	antiplatelet	drugs,	such	as	aspirin,	in	
pregnancy	reduced	the	risk	of	pre-eclampsia	and	other	adverse	outcomes	of	
pregnancy.	
In	2009,	Lisa	Askie	was	awarded	a	research	grant	from	the	UK	Medical	
Research	Council	for	further	methodological	research	using	the	pariS	dataset.	
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cardiovascular	disease	meta-analyses
international	trials	of	CHolesterol-lowering	drugs	
The	Cholesterol	Treatment	Trialists’	(CTT)	Collaboration	was	the	first	international	
prospective	meta-analysis	group,	established	in	1994	as	a	way	of	pooling	
individual-patient	data	from	many	trials	to	answer	research	questions	about	the	
effects	of	the	cholesterol-lowering	statin	drugs.	The	analysis	of	data	from	the	
subgroup	of	patients	with	diabetes	(in	14	trials	with	over	8000	vascular	events)	
was	published	in	2008.	This	confirmed	that	statin	therapy	reduced	the	risk	of	heart	
disease	mortality	in	people	with	diabetes	at	risk	of	vascular	disease.	
Data	from	25	trials	of	statins	compared	with	a	control	or	high-dose	compared	
with	low	-dose	statins	are	now	available.	These	patients	had	almost	25	000	vascular	
events,	such	a	large	number	that	analyses	of	many	subgroups	can	be	done	with	
statistical	precision.
asPirin	to	Prevent	reCurrent	venous	tHromboembolism?
The	investigators	of	aSpire	(page	26)	are	collaborating	with	the	investigators	of	the	
warfaSa	study	(initiated	in	Italy)	in	inSpire,	a	prospectively	designed	meta-analysis	
of	individual	patient	data.	The	two	groups	harmonised	their	protocols	to	allow	a	
prospective	meta-analysis	to	be	done.	The	study	aims	to	determine	whether	aspirin	
reduces	the	risk	of	recurrent	thromboembolism.
aCute	Coronary	Heart	disease
An	individual-patient-data	overview	of	immediate	coronary	angioplasty	or	
thrombolysis	for	the	treatment	of	acute	myocardial	infarction	has	shown	the	
benefits	of	angioplasty	and	the	importance	of	a	comprehensive,	unified	approach	to	
delivery	of	cardiac	care.
vigour	Collaboration:		
international	CardiovasCular	researCH	sinCe	1990
Data	from	the	1990s	guSto	trials	of	acute	myocardial	infarction	continue	to	be	
analysed.	A	study	of	nearly	50	000	patients	comparing	the	acute	mortality	and	
bleeding	risks	associated	with	162	mg	versus	325	mg	aspirin	showed	that	a	lower	
dose	of	aspirin	is	as	effective	as	the	higher	recommended	dose	for	patients	with		
ST-elevation	myocardial	infarction.
A	collaborative	study	of	136	247	patients	in	guSto	trials	and	other	trials	of	
the	vigour	collaboration	investigated	the	relationship	between	the	sex	of	the	
patient	and	mortality	in	the	30	days	after	they	presented	at	hospital	for	myocardial	
infarction	or	unstable	angina.	Women	had	a	higher	risk	of	death	than	men,	but	were	
on	average	older	and	had	more	risk	factors,	which	explained	most	of	the	differences.	
The	study	highlighted	the	differences	between	men	and	women	presenting	to	
hospital	for	acute	heart	disease.
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reviews	of	evidence	in	the	cochrane	Library
The	Cochrane	Library	publishes	systematic	reviews	of	the	evidence	in	many	
fields	of	health	care,	which	is	made	possible	by	specialist	groups	around	the	
world	that	prepare,	maintain	and	peer-review	these	studies	and	protocols	
for	studies.
The	CTC	is	the	editorial	base	of	the	Cochrane	Breast	Cancer	Group,	which	
has	infrastructure	support	from	the	Australian	Department	of	Health	and	
Ageing.	The	group	coordinates	the	Cochrane	reviews	on	breast	cancer	and	
maintains	a	specialised	register	of	over	7000	references.	A	current	project	
is	design	of	a	search	portal	to	broaden	public	access	to	breast	cancer	data.	
The	group	has	facilitated	the	publication	of	38	reviews	and	has	15	reviews	
in	progress.	CTC	members	of	the	group	have	published	reviews	themselves,	
most	recently	one	on	radiotherapy	for	ductal	carcinoma	and	another	
on	single-agent	compared	with	combined	chemotherapy	regimens	for	
metastatic	breast	cancer.
CTC	authors	also	write	systematic	reviews	for	the	Cochrane	Library	on	
other	topics.	In	2009,	two	systematic	reviews	of	evidence	on	treatments	for	
preterm	infants	were	published.		
fergus	tai,	Cochrane	breast	Cancer	review	group	trials	search	coordinator
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diversity	in	working	
for	tHe	australian	
trials	registry	and	CtC	
systematiC	reviews
An	objective	of	the	Australian	new	
Zealand	clinical	trials	registry	
(AnZctr)	is	to	reduce	bias	in	
medical	evidence.
‘In	my	role	as	a	systematic	reviews	
project	officer	I	promote	and	
implement	prospective	clinical	trial	
registration	through	the	AnZctr.	
By	creating	a	public	record	of	clinical	
trial	information,	our	registry	aims	
to	make	health	information	more	
accessible	and	transparent.	this	will	
ultimately	strengthen	the	efficacy,	
validity	and	value	of	the	medical	
evidence	base	used	to	inform	health	
care	decisions.	
‘I	am	also	involved	in	various	
research	projects	spanning	preterm	
infant	health,	prospective	meta-
analysis	methods,	and	obesity	
in	children.	the	diversity	of	my	
role	enables	me	to	broaden	my	
knowledge	and	keep	up	to	date	with	
the	latest	research	being	conducted	
across	the	full	spectrum	of	health.’
—	kylie	Hunter,
systematic	reviews	project	officer
worldwide	trial	search	through	the	wHo	portal:	
http://apps.who.int/trialsearch
lukas	staub	and	sally	lord
Evidence	from	clinical	trials
the	Australian	new	Zealand		
clinical	trials	registry
The	Australian	New	Zealand	Clinical	Trials	Registry	(anzctr)	provides	public	
data	on	trials	being	conducted	in	Australia,	New	Zealand,	the	neighbouring	
region,	as	well	as	some	trials	from	other	countries.	
The	number	of	trials	registered	has	grown	to	3657	since	it	started	in	2005.	
An	average	of	90	new	trials	are	submitted	for	registration	each	month,	an	
increase	from	the	2007	average	of	54.	About	17%	have	a	commercial	sponsor.
The	anzctr	is	a	primary	registry	in	the	World	Health	Organization’s	Registry	
Network,	the	portal	for	registered	trials	throughout	the	world.	The	WHO	has	
recently	introduced	universal	trial	numbers	(UTNs)	to	enable	trials	to	be	tracked	
more	easily.	Registry	manager	Lisa	Askie	represents	the	anzctr	on	the	WHO	
platform’s	Best	Practice	Group,	which	is	working	to	further	develop	minimal	
acceptable	standards	for	registries	throughout	the	world.	
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new MetHods for evAluAting diAgnostic tests 
the	clinical	value	of	a	new	diagnostic	test	is	ideally	assessed	by	randomised	
controlled	trials	that	measure	its	effect	on	health	outcomes.	this	evidence	is	rarely	
available,	and	test	accuracy	is	often	used	as	a	surrogate.	However,	accuracy	can	
only	be	estimated	if	a	reference	standard	is	available,	and	improved	accuracy	does	
not	necessarily	lead	to	better	health	for	the	patient.
In	the	absence	of	an	accepted	reference	standard,	information	that	goes	
beyond	‘classical’	test	accuracy	can	be	used	in	the	evaluation	of	a	new	test.	In	
collaboration	with	spine	surgeons,	dr	Staub	and	colleagues	designed	a	study	to	
measure	the	clinical	validity	of	the	so-called	nerve	root	sedimentation	sign,	which	
uses	imaging	for	diagnosis	of	lumbar	spinal	stenosis.
measuring	associations	between	test	results	and	their	downstream	consequences	
may	be	the	best	way	to	judge	the	clinical	validity	of	this	new	test.	this	approach	
takes	into	account	the	diagnostic	pathway	in	which	the	test	will	be	used,	requiring	
a	common	understanding	between	clinicians	and	epidemiologists	of	how	to	apply	
the	principles	of	test	evaluation	to	addressing	clinical	questions	about	tests.
lukas	staub	
Evaluating	clinical	tests
In	clinical	medicine,	tests	are	used	for	diagnosis	and	prognosis,	and	to	predict	the	outcome	of	
treatments.	Whether	a	test	is	known	to	be	accurate	is	not	enough	to	recommend	its	use	if	there	
is	uncertainty	about	the	effects	of	treatment.	When	new	tests	are	introduced,	the	benefit	of	
detection	must	be	weighed	against	the	risks	of	overinvestigation	and	overtreatment	due	to	possible	
misdiagnosis.	Evaluation	of	tests	is	a	major	research	strand	of	the	CTC’s	systematic	reviews	group.	
Knowing	whether	a	test	plus	treatment	will	improve	outcomes	requires	evidence.	The	best	evidence	
comes	from	clinical	trials.	However,	long-term	trials	may	not	always	be	necessary.	Sally	Lord	and	
colleagues	have	been	investigating	the	type	of	comparative	evidence	needed	for	test	evaluation.	They	
use	a	flow	diagram	of	a	hypothetical	randomised	trial	and	focus	on	specific	populations	and	outcomes	
where	the	new-test	pathway	differs	from	the	standard-test	pathway.
Sally	Lord	presented	an	invited	white	paper	for	the	US	Agency	for	Health	Care	Research	and	
Quality	at	the	launch	of	the	Diagnostic	Test	Evaluation	Work	Group,	which	is	developing	guidance	for	
conducting	comparative-effectiveness	reviews	of	diagnostic	technologies.
PHd
consecutive
sample
existing
tests
cross-classify treatment selection
vs new test cross-classify patient outcomes
vs new test
new
test
treatment
selection*
reference
standard
patient
outcomes
**
*based on combination of existing tests
**classical diagnostic accuracy studies
follow-upbaseline
reviews	of	new	technologies	and	
procedures	to	inform	decisions	
about	public	funding
The	CTC	has	a	contract	with	the	Medical	Services	
Advisory	Committee	(MSAC),	which	advises	the	
Australian	Minister	for	Health	and	Ageing	on	
evidence	relating	to	new	medical	technologies	and	
procedures.	CTC	staff,	with	clinical	experts,	review	the	
evidence	and	analyse	the	findings	relating	to	safety,	
effectiveness	and	cost-effectiveness.	
Nine	of	these	reviews	were	completed	in	
2008–2009.	Six	of	these	were	on	positron	emission	
tomography	(PET),	which	images	physiological	
function	and	metabolism,	complementing	
anatomical	information	from	computed	tomography	
or	magnetic	resonance	imaging.	PET	can	detect	
or	exclude	various	cancers	and	other	pathological	
processes.	The	other	reviews	related	to	ocular	
coherence	tomography	(an	imaging	technique	for	
retinal	eye	diseases)	and	tests	for	cervical	cancer.
luke	marinovich,	
sally	wortley	and	
stephanie	schoeppe	
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Can	survival	and	treatment	benefit	be	PrediCted	for	
individual	Patients?
dr	Lee’s	objective	is	to	develop	and	test	new	methods	of	analysing	data	from	past	
trials	of	breast,	colorectal	and	ovarian	cancer	to	assess	how	molecular	biomarkers	
and	other	disease	and	patient	characteristics	might	predict	survival	and	treatment	
benefit	.
He	is	also	examining	the	role	of	quality	of	life	in	predicting	response,	toxicity	and	
treatment	benefit	in	advanced	breast	cancer	patients.
Another	study	involves	constructing	a	risk	model	that	classifies	patients	into	high-
,	medium-	and	low-risk	in	terms	of	prognosis.	this	has	value	for	individualising	
treatment	decisions	and	for	future	stratification	of	patients	in	randomised	studies.
Various	hypotheses	have	arisen	from	the	completed	calypso	trial	of	ovarian	
cancer.	these	include	considering	cA125,	a	biological	marker,	as	a	surrogate	for	
treatment	efficacy	and	for	identifying	groups	of	patients	with	different	prognosis.
Every	patient	is	different
In	clinical	trials,	usually	the	benefits	and	harms	of	a	new	treatment	are	measured	
as	the	average	for	the	patient	group,	but	individual	patients	differ.	Trial	data	
are	now	being	used	to	predict	how	the	course	of	a	disease	differs	among	
patients	(prognosis)	and	how	patients	will	respond	individually	to	treatments	
(prediction).	Some	prognostic	and	predictive	factors	are:	risks	according	to	
biology;	lifestyle	risks;	and	attitudes	and	values.
Patients	may	therefore	be	interviewed	about	their	health	or	quality	of	life	or	
asked	to	allow	their	blood	samples	to	be	analysed	.	When	the	data	are	analysed	
as	part	of	a	trial,	the	results	help	clinicians	to	make	appropriate	decisions	for	
individual	patients.
risk	models	in	cancer	and	cardiovascular	disease
The	data	from	large	numbers	of	patients	in	the	CTC’s	clinical	trials	are	used	to	
calculate	the	risk	of	various	outcomes	in	comparable	populations.
Clinical	measures	and	genetic	and	biomarker	information,	individually	or	
together,	may	be	correlated	with	patient	outcomes	to	define	the	risk	of	an	
individual	patient	and	the	degree	of	benefit	an	individual	patient	might	have	
from	treatment.	Data	from	trials	has	been	used	to	build	risk	models	in	cancer	
and	cardiovascular	disease.
A	substudy	of	field	(page	24)	showed	that	self-reported	health	on	a	
pen-and-paper	scale	predicted	which	patients	were	at	higher	risk	of	major	
complications	of	diabetes.	A	10-point	difference	in	score	classified	later	risk	
better	than	a	1-unit	change	in	the	the	total	cholesterol-to-HDL	cholesterol	
ratio	or	a	10-year	longer	duration	of	diabetes.	field	data	have	also	been	used	
in	models	that	predict	of	the	risk	of	microvascular	disease,	such	as	amputations,	
kidney	disease	and	diabetic	eye	disease.
Chee	lee
PHd
deriving PAtient-vAlued utilities 
froM quAlity of life questionnAires 
to iMProve clinicAl decision MAking
dr	grimison	used	data	from	a	simple,	self-rated,	
disease-specific	questionnaire	in	three	breast	cancer	
trials	to	create	a	utility	index	based	on	cancer	patients’	
preferences.
the	index	can	be	used	to	generate	utility	scores	and	
quality-adjusted	life	years	in	clinical	trials.
the	aim	was	to	facilitate	the	integration	of	data		
about	health-related	quality	of	life	with	traditional		
trial	endpoints	(such	as	survival	and	tumour	response)	
and	ultimately	help	patients,	clinicians	and	funders		
make	better	decisions	about	cancer	treatments,	by	
considering	the	potential	trade-offs	between	survival		
and	quality	of	life.
Quality	of	life	information		
is	important	for	clinical	decisions
One	way	that	CTC	researchers	make	the	most	of	trial	evidence	is	by	incorporating	patient-oriented	
outcome	measures,	such	as	quality-of-life,	in	trials	where	possible.	Recently	published	studies	have	
focused	on	novel	ways	of	measuring	quality	of	life	and	explored	relationships	between	quality	of	
life	and	survival.
The	Patient	Disease	and	Treatment	Assessment	Form	was	designed	at	the	CTC	to	be	a	simple,	
pragmatic	measure	of	health-related	quality	of	life	in	people	with	advanced	cancer.	It	was	
validated	by	Anna	Nowak	and	colleagues	in	a	substudy	of	a	hepatocellular	carcinoma	treatment	
trial.	In	another	substudy,	Corona	Gainford	and	colleagues	adapted	and	translated	it	for	use	in	
Taiwan.
Individual	wellbeing	at	the	start	of	treatment	has	also	been	studied.	For	example,	in	a	study	by	
Lee	and	colleagues,	a	good	score	on	physical	wellbeing	and	appetite	at	baseline	predicted	longer	
survival	in	women	with	advanced	breast	cancer	treated	with	chemotherapy.
Peter	grimison
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translational	research
Translational	research,	often	described	as	‘from	bench	to	bedside’	is	the	
application	of	laboratory	research	to	patient	care.	Typically,	samples	of	blood	or	
tumour	tissue	are	collected	and	analysed	for	markers	that	correlate	with	clinical	
outcomes.	Biomarkers	may	forecast	survival	or	predict	the	response	of	a	patient	
to	a	treatment	—	an	important	part	of	personalised	medicine.
At	the	CTC,	so	far	about	a	quarter	of	trials	include	an	option	for	patients	
to	consent	to	biological	samples	being	used	in	research	or	being	banked	for	
future	research.	Genetic	testing	of	tissues	forms	part	of	the	process	of	screening	
potential	patients	for	recruitment	to	some	trials.	Linking	biological	and	clinical	
data	from	a	trial	creates	a	powerful	data	set.
In	2009,	Sonia	Yip	was	appointed	research	fellow	and	oncology	translational	
research	manager.	Translational	research	is	also	being	done	in	the	CTC’s	large	
cardiovascular	trials,	field	(page	24)	and	lipid	(page	26).
The	CTC	and	its	collaborative	groups	aim	to	build	translational	research	into	
their	trials	where	possible,	with	the	aim	of	future	applications	at	the	bedside.
sonia	yip,	translational		
research	manager
which	patients	
benefit	from	targeted	
chemotherapy	for		
colorectal	cancer?
A	secondary	study	of	C0.17	(a	
trial	of	cetuximab	therapy	in	
advanced	colorectal	cancer),	
published	in	the New England 
Journal of Medicine,	showed	
that	patients	with	a	K-ras	gene	
variant	did	not	benefit	from	
cetuximab.
In	identifying	the	group	
of	patients	who	would	not	
benefit,	the	study	thus	relieves	
future	patients	of	needless	
treatment	and	its	side-effects.	
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collaborations
The	CTC	works	with	organisations	around	the	world	in	collaborations	that	lead	to	better	health	
outcomes	in	Australia	and	internationally.	New	collaborations	are	continually	sought	and	then	
consolidated	in	research	projects	benefiting	the	health	of	Australians	and	others.	
group nature	of	group role	or	activity
amicable	collaboration Meta-analysis	collaboration:	international Member
ANZ	Breast	Cancer	Trials	Group	(anz	
bctg)
Collaborative	group	for	breast	cancer	trials:	Australia,	New	Zealand
International	collaborations:	International	Breast	Cancer	Study	Group	
(ibcSg),	Breast	International	Group	(BIG),	International	Breast	Cancer	
Intervention	Study	(ibiS)
Statistical	centre	for	group,	including	
randomisation
ANZ	Germ	Cell	Tumour	Study	Group		
(anz	gctg)
Collaborative	group	for	testicular	cancer	trials:	Australia,	New	Zealand Coordinating	centre
aSpire	Study	Group Collaborative	group	for	aspire	trial:	Australia,	New	Zealand,	United	
Kingdom,	India
Coordinating	centre
Australasian	Gastro-Intestinal	Trials	Group	
(agitg)
Collaborative	group	for	gastrointestinal	cancer	trials:	Australia,	New	
Zealand
International	collaborations:	nSabp	(USA),	ecog	(USA),	eortc	(Europe),	
petacc	(Europe),	ncic	ctg	(Canada),	octo	(UK)
Coordinating	centre
Australian	and	New	Zealand	Urogenital	
and	Prostate	Clinical	Trials	Group	(anzup)
Collaborative	group	for	cancer	of	the	genitourinary	system Coordinating	centre
Australasian	Society	of	Thrombosis	and	
Haemostasis
Professional	group	undertaking	thrombosis	trials:	Australia,	New	Zealand Coordinating	centre
Australasian	Lung	Cancer	Trials	Group	
(altg)
Collaborative	group	for	lung	cancer	trials
International	collaborations:	nvalt	(Netherlands),	ncic	ctg	(Canada)
Coordinating	centre
ANZ	Gynaecological	Oncology	Group	
(anzgog)
Collaborative	group	for	gynaecological	cancer	trials:	Australia,	New	
Zealand
International	collaborations:	Gynecological	Cancer	Intergroup	(gcig),	
Gynecologic	Oncology	Group	(GOG)
Coordinating	centre
Australian	New	Zealand	Clinical	Trials	
Registry	(anzctr)
National	register	of	Australian	clinical	trials Coordinating	centre
Australian	universities Members	of	the	Biostatistics	Collaboration	of	Australia Coordinating	centre
Biostatistics	Collaboration	of	Australia Collaborative	group	for	biostatistics	education:	national Coordinating	centre
Cochrane	Collaboration Collaborative	group	undertaking	systematic	reviews	of	trial	evidence:	
international
Editoral	base	of	the	Cochrane	Breast	Cancer	
Group;	co-convening	centre	for	Prospective	
Meta-analysis	Methods	Group
Cholesterol	Treatment	Trialists’	(CTT)	
collaboration
Collaboration	of	clinical	trial	groups	studying	cholesterol	treatments:	
Australia,	New	Zealand,	United	Kingdom,	United	States,	Italy
Coordination	of	meta-analyses	in	heart	
disease
Clinical	Trials	Development	Unit Joint	venture	with	Peter	MacCallum	Cancer	Institute Statistical	support	for	cancer	trials
Cooperative	Trials	Group	for	Neuro-
Oncology	(cogno)
Collaborative	group	for	brain	cancer	trials Coordinating	centre
Medical	Services	Advisory	Committee	
Department	of	Health	and	Ageing
Government:	Australia Provide	assessments	of	new	technologies	
and	other	research	services
Early	Prevention	of	Obesity	in	Children	
(epoch)	collaboration
Prospective	meta-analysis	collaboration:	international Data	coordination	centre
European	Organisation	for	Research	and	
Treatment	of	Cancer	(eortc)
International	collaborative	group Collaborator	through	Australian	groups
field	Study	Group Collaborative	group	for	field	diabetes	trial:	Australia,	New	Zealand,	Finland Coordinating	centre
coLLABorAtIonS	And	currEnt	trIALS
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group nature	of	group role	or	activity
Gynaecologic	Cancer	Intergroup	(gcig) International	collaborative	group Collaborator	through	ANZGOG
Gynecologic	Oncology	Group	(gog) International	collaborative	group Collaborator	through	ANZGOG
iniS	Study	Group Collaborative	group	for	inis	trial:	Australia,	New	Zealand,	United	Kingdom Regional	coordinating	centre
inSpire Meta-analysis:	aSpire	and	warfaSa	(Italy) Member
lipid	Study	Group Collaborative	group	for	follow-up	and	genetic	studies	of	lipid	cholesterol-
lowering	trial:	Australia,	New	Zealand,	Germany
Coordinating	centre
mappino	collaborative	group Meta-analysis	collaboration:	international Coordinating	centre
Medical	Research	Council	(mrc) Government:	international Collaborator
Menzies	Research	Institute	and	Charles	
Darwin	University
Research	institution:	Australia Collaborator	
National	Cancer	Institute	of	Canada	
Clinical	Trials	Group	(ncic	ctg)
Trials	research	group:	Canada Collaborator	through	Australian	cancer	
collaborative	groups
National	Heart	Foundation Nongovernment	organisation:	Australia Coordinator	of	the	lipid	trial
National	Perinatal	Epidemiology	Unit	
(npeu),	University	of	Oxford
Research	institution:	UK Co-collaborator	on	the	iniS	neonatal	trial
National	Surgical	Adjuvant	Breast	and	
Bowel	Project	(nSabp)
Collaborative	group Collaborator	through	Australian	groups
NeOProM	collaborative	group Prospective	meta-analysis	collaboration;	international Coordinating	centre
NSW	Cancer	Council Cancer	Epidemiology	Research	Unit Collaborator
NSW	Cooperative	Oncology	Group Collaborative	group:	NSW Coordinating	centre	for	the	group
Oxford	Clinical	Trials	Office	(octo) Trials	research	group:	UK Cancer	trials
PARIS	collaborative	group Meta-analysis	collaboration	with	representation	from	many	countries Co-coordinating	centre
PreVILIG	collaborative	group Meta-analysis	collaboration;	international Coordinating	centre
Primary	Care	Cooperative	Cancer	Clinical	
Trials	Group	(PC4)
Collaborative	group:	Australia Collaborator	through	the	Clinical	Trials	
Development	Unit
Primary	Coronary	Angioplasty	versus	
Thrombolysis	(pcat)
Meta-analysis	collaboration	with	representation	from	many	countries Co-coordinating	centre
Prospective	Pravastatin	Pooling	project Collaborative	group:	Australia,	New	Zealand,	United	States,	Scotland Coordinating	centre
Royal	Australasian	College	of	Surgeons	
(racS)
Professional	society	undertaking	trials	of	surgery:	Australia	and	New	
Zealand
Coordinating	the	SNAC	trial	in	breast	cancer	
with	the	racS
Star	Child	Health International	collaboration Member
vigour	group Collaborative	group	for	trials	of	heart	disease:	40	countries Data	coordinating	centre,	Asia-Pacific	
region;	international	statistical	centre	
(hero-2	trial)
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current	trials
trial	 Participants status
breast	cancer
SNAC	2:	Multicentre	randomised	trial	of	sentinel-node	biopsy	versus	axillary	
clearance
NHMRC	CTC	study
Women	with	operable	breast	cancer,	stratified	
by	various	factors,	including	age	and	tumour	
size
Recruitment	target:	1012
Recruitment:	131
gastrointestinal	cancer
Current	trials
CO.20:	phase	II	randomised	study	of	brivanib	alaninate	+	cetixumab	versus	
placebo	+	cetuximab	in	metastatic	carcinoma	(AG0207CR)
NCIC	CTG	and	AGITG	study
Patients	with	treated	metastatic	colorectal	
cancer	of	K-ras	wild	type
Recruitment	target:	370
Recruitment:	312
Quasar	2:	phase	III	study	of	capecitabine	and	bevacizumab	as	adjuvant	
treatment	of	colorectal	cancer	(AG0107CR)
OCTO	study
Patients	with	colon	cancer	treated	by	surgery Recruitment	target:	250
Recruitment:	189
REGISTER:	multicentre	phase	II	study	of	risk	evaluation	in	GIST	with	
selective	therapy	escalation	for	response	(AG0507GS)
AGITG	study
Patients	with	gastrointestinal	stromal	tumour	
not	suitable	for	curative	surgery
Recruitment	target:	80
Recruitment:	8
PETACC	6:	addition	of	capecitabine	to	preoperative	oxaliplatin	
chemoradiotherapy	and	postoperative	oxaliplatin	chemotherapy	for	rectal	
cancer	(AG0707R)
EORTC	study
Patients	with	locally	advanced	rectal	cancer Recruitment	target:	100
Recruitment:	19
TOP	GEAR:	randomised	phase	II–III	trial	of	preoperative	chemoradiotherapy	
versus	preoperative	chemotherapy	for	gastric	cancer	(AG0407GR)
AGITG	study
Patients	with	resectable	gastric	cancer	suitable	
for	these	treatments
Recruitment	target:		
120	(stage	1);	632	(stage	2)
Recruitment:	3
Pending	trials
A	la	CART:	Australasian	laparoscopic	cancer	of	the	rectum,	phase	III	
randomised	trial	of	laparascopy-assisted	resection	with	open	resection	
(AG0109CS)
AGITG	study
Patients	with	primary	rectal	cancer Recruitment	target:	470
ATTACHE:	Timing	of	surgery	and	adjuvant	chemotherapy	for	hepatic	
metastases	from	colorectal	cancer	(AG1209CL)
AGITG	study
Patients	with	colorectal	cancer	and	resectable	
liver	metastases	and	no	extrahepatic	disease
Recruitment	target:	200
ATTAX	3:	Phase	II	study	of	docetaxel,	cisplatin	and	fluoropyrimidine	with	or	
without	panitumumab	for	oesophagogastric	cancer	(AG0607OG)
AGITG	study
Patients	with	metastatic	or	locally	recurrent	
oesophagogastric	cancer
Recruitment	target:	100
LAP07:	randomised	multicentre	phase	III	study	of	gemcitabine	with	
or	without	chemoradiotherapy	and	with	or	without	erlotinib	for	
adenocarcinoma	of	the	pancreas	(AG0208PS)
AGITG	and	GERCOR	study
Patients	with	locally	advanced	adenocarcinoma	
of	the	pancreas
Recruitment	target:	60
SCOT:	Short-course	oncology	therapy,	a	study	of	adjuvant	chemotherapy	in	
colorectal	cancer	(AG0308CR)
AGITG	study
Patients	with	fully	resected	stage	III	colorectal	
cancer
Recruitment	target:	225
SURGIST:	Phase	III	randomised	study	of	surgery	of	residual	disease	
(AG0108GS)
EORTC	study
Patients	with	metastatic	gastrointestinal	
stromal	tumor	responding	to	imatinib	
mesylate
Recruitment	target:	35	(ANZ);		
350	(international)
SUPER:	Phase	III	trial	evaluating	surgical	resection	of	the	primary	tumour	in	
metastatic	colorectal	cancer	(AG	0209CRS)
Patients	with	unresectable	metastatic	
colorectal	cancer
Recruitment	target:	400
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trials	in	follow-up
Da	Vinci:	Phase	III	trial	of	irinotecan	versus	irinotecan	+	De	Gramont	
schedule	5-fluorouracil	and	folinic	acid	for	colorectal	cancer	(AG0103CR)
AGITG	study
Patients	with	treated	metastatic	colorectal	
cancer
Recruitment	target:	100
Recruitment:	89
EORTC	62024:	Randomised	trial	of	adjuvant	imatinib	mesylate	(Glivec)	
versus	no	further	therapy	after	complete	surgery
EORTC	study
Patients	with	fully	resected	gastrointestinal	
stromal	tumour
Recruitment:	81
Gofurtgo:	Phase	II	study	of	fixed-dose	rate	gemcitabine–oxaliplatin	with	
5-fluorouracil	and	radiotherapy	for	pancreatic	cancer	(AG0503P)
AGITG	study
Patients	with	localised	pancreatic	cancer Recruitment:	48
C06:	Oral	uracil	and	ftorafur	+	leucovorin	compared	with	5-fluorouracil	+	
leucovorin	for	colon	carcinoma	
NSABP	study
Patients	with	stage	II	or	stage	IIII	
adenocarcinoma,	no	metastatic	disease	and	a	
life	expectancy	(excluding	cancer)	of	at	least	
10	years
Recruitment:	11
C07:	5-fluorouracil	plus	leucovorin	compared	with	oxaliplatin	with	
5-fluorouracil	+	for	stages	II	and	III	carcinoma	of	the	colon
NSABP	study
Patients	with	resected	stage	II	or	stage	III	colon	
carcinoma
Recruitment:	134
EORTC	62005:	Phase	III	study	of	two	different	doses	of	imatinib	mesylate	for	
CD117-expressing	metastatic	or	unresectable	gastrointestinal	stromal	tumor
EORTC	study
Patients	with	metastatic	gastrointestinal	
stromal	tumour
Recruitment:	116
EORTC	40983:	Phase	III	preoperative	and	postoperative	chemotherapy	
with	oxaliplatin	+	5-fluorouracil	+	leucovorin	versus	surgery	alone	for	liver	
metastases	of	colorectal	origin
EORTC	Study
Patients	with	colon	cancer	with	resectable	liver	
metastases
Recruitment:	35
ESPAC-3:	European	study	of	adjuvant	chemotherapies	in	resectable	
pancreatic	cancer	
ESPAC	study
Patients	with	operated	cancer	of	the	pancreas Recruitment:	133
gynaecological	cancer
Current	trials
PORTEC	3:	Phase	III	trial	comparing	concurrent	chemo	radiation	and	
adjuvant	chemotherapy	with	pelvic	radiation	alone	in	high-risk	endometrial	
carcinoma
CGOG	and	ANZGOG	study
Women	with	advanced	endometrial	carcinoma Recruitment	target:	200	(ANZ);	500	
(international)
Recruitment:	33	(ANZ);	133	
(international)
Symptom	benefit:	Palliative	chemotherapy	for	ovarian	cancer	
(ANZGOG0701)
ANZGOG	and	PoCoG	study
Women	with	platinum-resistant	epithelial	
ovarian	cancer
Recruitment	target:	100
Recruitment:	56
OVAR	16:	Phase	III	study	of	pazopanib	versus	placebo	for	epithelial	ovarian,	
fallopian	tube	or	primary	peritoneal	cancer
ANZGOG	study
Women	with	stage	II–IV	ovarian	fallopian	
tube	or	primary	peritoneal	cancer	that	has	not	
progressed	after	first-line	treatment
Recruitment	target:	50	(ANZ);	900	
(international)
Recruitment:	14	(ANZ)	
Accelerated	BEP:	Feasibility	study	of	accelerated	BEP	as	first-line	
chemotherapy	for	advanced	germ	cell	tumours	(ANZGCTG0206,	
ANZGOG0603)
ANZUP	and	ANZGOG	study
Patients	with	intermediate	and	poor-risk	
advanced	germ	cell	tumours	(and	selected	
good-risk	tumours)
Recruitment	target:	25	(revised	to	
45	in	2009)
Recruitment:	32
Pending	trials
ICON	6:	Placebo-controlled	trial	of	concurrent	cediranib	and	chemotherapy	
versus	chemotherapy	alone	(stage	2)	and	of	maintenance	cediranib	versus	
placebo	after	concurrent	cediranib	and	chemotherapy	(stage	3)
ANZGOG	study
Women	with	platinum-sensitive	relapsed	
ovarian	cancer
Recruitment	target:	100	(stage	2);	
400	(stage	3)
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Outback:	Phase	III	trial	of	addition	of	adjuvant	chemotherapy	to	standard	
chemoradiation	as	primary	treatment	for	cervical	cancer
ANZGOG	study
Women	with	locally	advanced	cervical	cancer Recruitment	target:	780
PARAGON:	phase	II	study	of	anastrozole	in	gynaecological	cancers
GCIG	study
Women	with	potentially	hormone-responsive	
gynaecological	cancers
Recruitment	target:	100	(ANZ)
trials	in	follow-up
TRIPOD:	Phase	II	trial	of	intraperitoneal	chemotherapy	(ANZGOG0601)
ANZGOG	study
Women	with	ovarian	and	related	cancers Recruitment:	39
ICON	7:	Randomised,	two-arm,	multicentre	GCIG	trial	of	adding	
bevacizumab	to	standard	chemotherapy	for	epithelial	ovarian	cancer
GCIG	study
Women	with	epithelial	ovarian	cancer	who	
have	not	received	systemic	antitumour	therapy
Recruitment:	76	(ANZ);			
1528	(international)
SCOTROC	4:	Multicentre	randomised	trial	of	carboplatin	flat	dosing	vs	
intrapatient	dose	escalation	in	first-line	chemotherapy	
Women	with	ovarian,	fallopian	tube	or	
peritoneal	carcinoma	who	are	unsuitable	for	
platinum–taxane	therapy
Recruitment:	64
Tarceva:	phase	III	study	of	erlotinib	versus	observation	(EORTC	55041) Women	with	high-risk	stage	I	or	stages	II–IV	
ovarian	cancer	which	has	not	progressed	after	
platinum	chemotherapy
Recruitment:	42
Phase	III	randomised	trial	of	paclitaxel	+	carboplatin	versus	triplet	or	
sequential	doublet	combinations	for	epithelial	ovarian	or	primary	peritoneal	
carcinoma	(GOG	182)
Women	with	advanced	(stage	III	or	IV)	primary	
ovarian	or	peritoneal	cancer
Recruitment:	183
Prospective	study	of	risk-reducing	salpingo-oophorectomy	and	longitudinal	
CA-125	screening	among	women	at	increased	genetic	risk	of	ovarian	cancer	
(GOG	199)
Women	aged	>30	at	risk	of	ovarian	cancer Recruitment:	83
genitourinary	cancer
Accelerated	BEP:	feasibility	study	of	accelerated	BEP	as	first-line	
chemotherapy	for	advanced	germ	cell	tumours	(ANZGCTG0206,	
ANZGOG0603)
ANZUP	and	ANZGOG	study
Patients	with	intermediate	and	poor-risk	
advanced	germ	cell	tumours	(and	selected	
good-risk	tumours)
Recruitment	target:	25		
(revised	to	45	in	2009)
Recruitment:	32
Aprepitant	for	germ	cell	chemotherapy:	phase	II	multicentre	trial	of	a	7-day	
aprepitant	schedule	to	prevent	chemotherapy-induced	nausea	and	vomiting	
(ANZGCTG0801)
ANZUP	study
Patients	receiving	cisplatin-based	
chemotherapy	for	germ	cell	tumours
Recruitment	target:	50
Recruitment:	19
Chemo	&	cognition:	cognitive	function	and	treatment	for	testicular	cancer	
(ANZGCTG0106)
ANZUP	study
Patients	being	treated	and	followed	up	for	
testicular	cancer
Recruitment	target:	154
Recruitment:	75
SORCE:	Adjuvant	sorafenib	for	renal	cell	carcinoma
MRC	(UK)	and	ANZUP	study
Patients	with	resected	renal	cell	carcinoma	at	
intermediate	or	high	risk	of	relapse
Recruitment	target:	250	(ANZ);		
1656	(international)
Recruitment:	17	(ANZ)
lung	cancer
Current	trials
NITRO:	Phase	III	multicentre	trial	of	adding	nitroglycerine	to	first-line	
chemotherapy	for	advanced	non-small-cell	lung	cancer	
ALTG	study
Patients	with	advanced	non-small-cell	lung	
cancer
Recruitment	target:	500
Recruitment:	35
PACT	in	NSCLC:	Preferences	for	adjuvant	chemotherapy	in	non-small-cell	
lung	cancer	
ALTG	study
Patients	with	non-small-cell	lung	cancer,	
surgeons	and	oncologists
Recruitment	target:	200
Recruitment:	29
BR.29:	Phase	III	randomised	trial	of	adjuvant	cediranib	vs	placebo	with	
paclitaxel–carboplatin	chemotherapy	for	non-small-cell	lung	cancer
NCIC	CTG	and	ALTG	study
Patients	with	advanced	or	metastatic	non-
small-cell	lung	cancer
Recruitment	target:	100	
(international)
Recruitment:	25	(ANZ)	39	
(international)
Pending	trials
BR.26:	Phase	III	trial	of	PF-804	in	patients	wtih	incurable,	non-small	cell	
lung	cancer
Patients	with	stage	IIIB	or	IV	non-small	cell	
lung	cancer
Recruitment	target:	720	
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B2P2M2:	Phase	II	trial	of	BNC105P	as	second-line	chemotherapy	
for	pleural	mesothelioma
Patients	with	pleural	mesothelioma	which	has	
progressed	after	pemetrexed	and	platinum	
chemotherapy
Recruitment	target:	60
trials	in	follow-up
MATES:	Maintenance	thalidomide	in	mesothelioma
NVALT,	ALTG	study
Patients	with	malignant	pleural	mesothelioma,	
after	first-line	chemotherapy
Recruitment:	14	(ANZ),	200	
(international)
brain	cancer
Current	trials
LGG:	Phase	III	study	of	primary	chemotherapy	with	temozolomide	versus	
radiotherapy	for	low-grade	glioma	(TROG	06.01)
COGNO	and	TROG	study
Patients	with	low-grade	glioma,	stratified	for	
genetic	1p	loss
Recruitment	target:	699	
(international),	100	(ANZ
Recruitment:	100	(ANZ)
Phase	III	study	of	temozolomide	and	short-course	radiation	versus	radiation	
alone	for	glioblastoma	multiforme	in	elderly	patients	(TROG	08.02)
COGNO	and	TROG	study
Elderly	patients	with	new	glioblastoma	
multiforme
Recruitment	target:	100
Recruitment:	24
Pending	trials
CATNON:	Phase	III	trial	of	concurrent	and	adjuvant	temozolomide	
chemotherapy	anaplastic	glioma	(EORTC	26053-22054)
EORTC	study
Patients	with	non-1p/19q-	deleted	anaplastic	
glioma
Recruitment	target:	100	(ANZ);	748	
(international)
Cabaret:	Phase	II	study	of	carboplatin	and	bevacizumab	in	for	glioma
COGNO	study
Patients	with	recurrent	grade	IV	glioblastoma	
multiforme	following	radiotherapy	and	
temozolomide	chemotherapy
Recruitment	target:	120
Phase	II	study	of	acetazolamide	plus	dexamethasone	versus	dexamethasone	
for	cerebral	oedema	in	glioblastoma
COGNO	study
Patients	with	glioblastoma	requiring	new	
dexamethasone	or	dose	increase	due	to	
progressive	or	recurrent	disease
Recruitment	target:	86
Phase	II	study	of	psycho-educational	intervention	in	patients	with	primary	
brain	tumour
PoCoG	led,	COGNO	cobadged	study
Patients	with	confirmed	primary	brain	tumours Recruitment	target:	60
trials	in	follow-up
Temozolomide	and	caelyx	study	(P05036)
COGNO	study
Patients	with	glioblastoma	multiforme	treated	
with	radiotherapy	and	chemotherapy
Recruitment:	40
Cardiovascular	disorders
Current	trials
ASPIRE:	Aspirin	to	prevent	recurrent	venous	thromboembolism People	who	have	had	6	months	of	treatment	
with	warfarin	for	a	venous	thromboembolism
Recruitment	target:	2000
Recruitment:	657
trials	in	follow-up
FIELD:	Fenofibrate	Intervention	and	Event	Lowering	in	Diabetes Patients	with	type	2	diabetes Recruitment:	9795
LIPID:	Long-Term	Intervention	with	Pravastatin	in	Ischaemic	Disease Patients	with	a	history	of	coronary	heart	
disease
Recruitment:	9014
neonatal	disorders
Current	trials
BOOST	II:	Benefits	of	Oxygen	Saturation	Targeting Neonates	born	before	28	weeks’	gestation Recruitment	target:	1200
Recruitment:	846
APTS:	Australian	Placental	Transfusion	Study Neonates	born	before	30	weeks’	gestation Recruitment	target:	1200
Recruitment:	6	(ANZ)
trials	in	follow-up
INIS:	International	Neonatal	Immunotherapy	Study Neonates	with	infection	and	low	birthweight	
who	are	taking	antibiotics
Recruitment:	1398	(ANZ);	3493	
(international)
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Rebecca	Mister,	BSc,	MSc
Kathleen	Scott,	BSc(hons),	PhD
QuALIty	ASSurAncE
Phillipa	Smith,	BPharm(hons),	MSc,	head	of	
quality	assurance
Karen	Pinto,	DipTeach,	BA,	PostgradDip	
Psychol,	AGITG	and	ANZGOG	trial	audit	
coordinator
cAncEr	trIALS
Martin	Stockler,	MB	BS(hons),	MSc,	FRACP,	
cancer	trials	co-director	and	associate	
professor
Mamta	Bagia,	MB	BS,	DipPalMed,	FRACP,	
clinical	research	fellow
Corona	Gainford,	MB	BCh,	BAO(hons),	MSc,	
MRCP	(UK),	clinical	research	fellow
Peter	Grimison,	BSc(Med)	MB	BS(hons),	
FRACP,	clinical	research	fellow
Sonia	Yip,	BSc(hons),	PhD,	oncology	
translational	research	fellow	(from	Dec	
2009)
managers
Burcu	Vachan,	BSocSc(hons),	MPH,	oncology	
program	manager
Danielle	Miller,	BSc(hons),	MPH,	oncology	
program	manager	(Nov	2008–May	2009)
Amy	Boland,	BPsych(hons),	GradCertHlthSc,	
associate	program	manager,	ANZUP
Karen	Bracken,	BEc,	MPH,	associate	program	
manager,	ANZ	BCTG
Xanthi	Coskinas,	BSc,	GradDipHIM,	associate	
program	manager,	SNAC	trials,	and	ALTG
Reena	Gill,	BSc,	MPH,	CCRP,	associate	
program	manager,	AGITG
Julie	Martyn,	PhD,	associate	program	
manager,	ANZGOG
Ann	Ratcliffe,	RN,	MHlthServMgt,	associate	
program	manager,	COGNO
Justine	Simard-Lebrun,	BA,	associate	program	
manager,	ANZUP	
Kate	Wilson,	BA,	MPH,	associate	program	
manager,	AGITG
Nicole	Wong,	RN,	BN,	BSc(hons),	associate	
program	manager,	AGITG
Sonia	Yip,	BSc(hons),	PhD,	oncology	program	
manager	(Jun–Nov	2009)
oncology	trials	staff
Kass	Adams,	BAppSc(hons),	MPH
Hani	Adhami,	BAppSc,	MHlthSc
Christine	Aiken,	BSocSc,	MHlthSc
Amasy	Alkhateeb,	BSc(hons)
Claire	Banks,	BAppSc,	MPH
Radhika	Butala,	MIPH,	BHMS
Kerrie	Carlton,	BAppSc,	MSc
Sarah	Chinchen,	BSc(hons),	MPH
Michelle	Cummins,	BSc,	PhD
Mausam	Doctor	BSc,	MSc,	GradCertCDM
Megan	Evans,	BAppSc
Alyson	France,	BSc/	BTeach,	GradDipAppSc
Natalie	Galbraith,	BSc
Kim	Gillies	BA(hons),	MHlthSc
Stephanie	Green,	BBioMedSc,	MPH
Merryn	Hall,	BSc
Christina	Halteh,	BSc(hons)
Sarah	Harvey,	BMedSc
Felicity	Howard,	BAppSc,	GradCertHSM
Rebecca	James,	BA–BSc,	GradDipEd
Dildeep	Kaur,	BHMS,	DNHE,	MPH
Joon	Kim
Ilka	Kolodziej,	BAppSc(hons)
Alan	Lucas,	BAppSc
Lisa	Martyn,	BAppSc
Ruby	Masson,	BSc(hons),	PGDipSc
Angus	McDonald,	BEc(SocSc)
Julia	Messer,	BSc
Helen	Mueller,	BSc,	MSc
Vivienna	Ong,	BSc
Natalie	Plant,	BSc,	BSc(hons),	MHlthSc
Julie	Poulter
Jené	Roestorf,	BSc,	MAppSc
Kate	Roff,	BSc(hons)
Robyn	Secomb,	BA,	RN
Bhagwant	Sekhon,	BSc,	MHerbMed
Julia	Shoulder,	BSc(hons)
Lindsay	Stevens
Shona	Sylvester,	BSc
Raymond	Tangunan,	BAppSc
Jennifer	Thompson
Eric	Tsobanis,	BScN(hons),	MBA
Caitlin	van	Holst	Pellekaan,	BMedSc(hons)
Giridhar	Vemulapalli,	BSc,	MAppSc
Lakshmi	Waniganayake,	BDS,	MPH
Brooke	Wilson
ASpIrE	trIAL
Rebecca	Mister,	BSc,	MSc,	project	manager
Sarah	Chinchen,	BSc(hons),	data	manager–
study	monitor
Caitlin	van	Holst	Pellekaan,	BMedSc(hons),	
clinical	trial	assistant
nEonAtAL	trIALS
William	Tarnow-Mordi,	MRCP(UK),	FRCPCH,	
coordinator	of	neonatal	trials
InIS	trial
Lucille	Sebastian,	BSc(hons),	PhD,	project	
manager
Caitlin	van	Holst	Pellekaan,	BMedSc(hons),	
clinical	trial	assistant
BooSt	II	trial
Alpana	Ghadge,	BSc,	MSc,	PhD,	GradCert	
TradeMarksLawPract,	project	manager
Ilka	Kolodziej,	BAppSc(hons),	data	manager
FIELd	trIAL
Li	Ping	Li,	BMed,	GradCertDM,	safety	
and	outcomes	manager	and	substudy	
coordinator
San	Yip	Chan,	administrative	assistant
Sandra	Healey,	BA(hons),	GradDipFA,	RN,	
substudy	coordinator
Rachel	O’Connell,	BMath,	MMedStat,	field	
statistics	group	manager
Rhana	Pike,	MA,	GradCert,	ELS,	CMPP,	writer	
(from	Oct	2008)
Dana	Tse,	BMedSc(hons),	PhD,	writer	(to	Sep	
2008)
Jun	Zhang,	BMed,	MHIM,	data	manager,	
pathology	coordinator
LIpId	FoLLow-up	Study
Helen	Pater,	BAppSc,	project	manager
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SyStEmAtIc	rEVIEwS	And	HEALtH	
cArE	ASSESSmEnt
Lisa	Askie,	BN,	MPH,	PhD,	director,	and	senior	
research	fellow
Sally	Lord,	MB	BS,	DipPaed,	MS,	FRACGP,	
epidemiologist	and	research	fellow
Jenny	Chow,	AssocDip,	executive	officer
medical	Services	Advisory	committee	
review	group
Suzanne	Dyer,	BSc(hons),	GradCertPH,	PhD,	
manager	(to	Aug)
Luke	Marinovich,	BA(hons),	MPH,	manager	
(from	Aug)
Samara	Lewis,	BA/BSc(hons),	PhD,	project	
manager
Wei	Lei,	BMed,	MM,	project	officer
Michelle	McIsaac,	BSc(hons),	M	HlthEcon,	
health	economist
Stephanie	Schoeppe,	MSocSc,	project	officer
Lukas	Staub,	Dr	med,	DAS,	project	officer	and	
PhD	student
Fergus	Tai,	BAppSc,	DipIT,	project	officer
Sally	Wortley,	BRehabClng(hons),	MPH,	
project	officer
cochrane	Breast	cancer	review	group
Sharon	Parker,	RN,	BHSc,	MPH,	group	
coordinator
Nicole	Holcroft,	BSc(hons),	trial	search	
coordinator
Fergus	Tai,	BAppSc,	DipIT,	project	officer
Australian	new	Zealand		
clinical	trials	registry
Lisa	Askie,	BN,	MPH,	PhD,	manager,	and	
senior	research	fellow
Nicole	Holcroft,	BSc(hons),	project	officer
Kylie	Hunter,	BA,	BA(hons),	project	officer
William	Ooi,	MHlthSc,	BAppSc,	project	officer
Emma	Smith,	BSc(hons),	MSc,	PhD,	senior	
project	officer
Fergus	Tai,	BAppSc,	DipIT,	project	officer
Suchaya	Thongyoo,	BAppSc,	research	
assistant
Thuyen	Vu,	BSc,	project	officer
Systematic	review	projects
Angela	Carberry,	BAppSc,	BHlthSc(hons),	
project	officer
Kylie	Hunter,	BA,	BA(hons),	project	officer
Henry	Ko,	BEng(Med)(hons),	GradIEAust,	
project	officer
Charlene	Thornton,	BN,	GradDipMid,	MSc,	
project	officer
Wei	Lei,	BMed,	MM,	project	officer
Health	economics
Deborah	Schofield,	BSpPath,	GradDipComp,	
PhD,	professor
Emily	Callander,	BA,	research	officer
Rupendra	Shrestha,	MSc,	PhD,	research	fellow
Hannah	Verry,	BEc,	health	economist
BIoStAtIStIcS	And	conSuLtIng
Val	Gebski,	BA,	MStat,	professor	and	principal	
research	fellow
Malcolm	Hudson,	BSc(hons),	PhD,	honorary	
professor
Kew	Flood,	administrative	officer
Senior	biostatisticians
Karen	Byth,	BSc(hons),	MSc,	PhD,	DIC,	CStat	
RSS,	senior	lecturer
Peta	Forder,	BSc(hons),	MPH,	MBiostat,	
lecturer
Adrienne	Kirby,	BSc(hons),	MSc,	senior	
lecturer
Andrew	Martin,	BA,	MA,	GradDip,	PhD,	AStat,	
senior	lecturer	
Biostatisticians
Elizabeth	Barnes,	BAppSc,	MStat
Christopher	Brown,	BSc
Mark	Chatfield,	BA,	MSc
Mark	Donoghoe,	BSc(hons)
Kristy	Mann,	BScAgr(hons)
Alistair	Merrifield,	MSc,	PhD
Rachel	O’Connell,	BMath,	MMedStat
Anne-Sophie	Veillard,	BSc,	MSc
Merryn	Voysey,	GradDipMathStat,	MBiostat
Diana	Zannino,	BSc(hons),	MSc
Biostatistics	collaboration	of	
Australia	(BcA)
Erica	Jobling,	executive	officer
Sarah	Goodman-Jones,	administrative	
assistant	(to	Nov	2008)
Andrew	Yip,	administrative	assistant	(from	
Nov	2008)
puBLIcAtIonS
Rhana	Pike,	MA,	GradCert,	ELS,	CMPP,	senior	
publications	officer
InFormAtIon	SyStEmS
Colin	Sutton,	BSc,	MSc,	IT	systems	
development	manager
Infrastructure
Dinh	Tran,	BMath,	MCompSc,	infrastructure	
manager
Asanka	Perera,	BSc,	computer	systems	officer
Thuyen	Vu,	BSc,	computer	systems	officer
database	administration
Anh	Tai	Nguyen,	BMath,	database	manager
Software	engineers
Seshu	Atluri,	BE
Ravinder	Singh,	BTech
BuSInESS	AdmInIStrAtIon
Kim	Russell-Cooper,	BA(hons),	MBA,	general	
manager
Cynthia	Carr,	BEd,	HRD,	human	resources	and	
administration	manager
Suzanne	Everett,	BSW,	human	resources	and	
administration	coordinator
Maki	Joseph,	DipEd,	finance	officer
Agnes	Ho,	MPracAcc,	CPA,	finance	officer
Anne	Madden,	BA,	executive	officer
Jackie	McGrath,	administrative	assistant
Faith	Papuni,	personal	assistant	to	the	deputy	
director
Doris	Rattos,	administrative	assistant
Frank	Schoenig,	administrative	assistant
Bebe	Sim,	MAcc,	CPA,	finance	manager
Carlos	Sterling,	BEng,	MBA,	finance	officer
Nina	Stromqvist,	BFA(hons),	grants	
coordinator
rESEArcH	StudEntS
Prunella	Blinman,	BMed,	FRACP
Peter	Grimison,	BSc(Med),	MB	BS(hons),	
FRACP,	PhD
Chee	Lee,	MB	BS(hons),	MMedSc,	MBiostat,	
FRACP
Belinda	Kiely,	BSc(Med),	MB	BS,	FRACP
Kushwin	Rajamani,	MB	BCh
Michaella	Smith,	BSc,	MB	BS(hons),	MMSc
Lukas	Staub,	Dr	med,	DAS,
Ru-Dee	Ting,	MB	BS,	FRACP
AcAdEmIc	StAFF
Lisa	Askie,	BN,	MPH,	PhD,	senior	research	
fellow
Christopher	Brown,	BSc,	research	fellow
Karen	Byth,	BSc(hons),	MSc,	PhD,	DIC,	CStat	
RSS,	senior	lecturer
Peta	Forder,	BSc(hons),	MPH,	MBiostat,	
lecturer
Corona	Gainford,	MB	BCh,	BAO(hons),	MSc,	
MRCP	(UK),	clinical	research	fellow
Val	Gebski,	BA,	MStat,	principal	research	
fellow	and	professor
Wendy	Hague,	MB	BS,	MBA,	PhD,	senior	
research	fellow
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Anthony	Keech,	MB	BS,	MSc,	FRACP,	principal	
research	fellow	and	professor
Adrienne	Kirby,	BSc(hons),	MSc,	senior	
lecturer
Sally	Lord,	MB	BS,	DipPaed,	MS,	FRACGP,	
research	fellow
Andrew	Martin,	BA,	MA,	GradDip,	PhD,	AStat,	
senior	lecturer	
Deborah	Schofield,	BSpPath,	GradDipComp,	
PhD,	professor
John	Simes,	BSc(Med)(hons),	MB	BS(hons),	
MD,	SM,	FRACP,	senior	principal	research	
fellow	and	professor
Martin	Stockler,	MB	BS(hons),	MSc,	FRACP,	
associate	professor
Sonia	Yip,	BSc(hons),	PhD,	research	fellow	
Diana	Zannino,	BSc(hons),	MSc,	research	
fellow
Honorary	associates	of	the	ctc
Dr	Meera	Agar,	COGNO
Dr	Sally	Baron-Hay,	ANZGOG
Dr	David	Bernshaw,	ANZGOG
Dr	Andrew	Biankin,	LAP07
Dr	Alex	Boussioutas,	AGITG
Dr	Alison	Brand,	ANZGOG
Dr	Timothy	Brighton,	ASPIRE
Dr	Michael	Brown,	MTAP
Dr	Ian	Campbell,	SNAC	2
Professor	Christopher	Christophi,	AGITG		
Associate	Professor	Philip	Clarke,	Health	
Economics
Dr	Andrew	Davidson,	NITRO
Associate	Professor	Ian	Davis,	ANZUP
Dr	Jayesh	Desai,	REGISTER
Dr	Katherine	Drummond,	COGNO
Dr	Vlatka	Duric,	Preferences	studies
Dr	John	Eikelboom,	PREDICT
Dr	Jonathan	Fawcett,	AGITG	
Dr	Kathryn	Field,	CABARET
Dr	Michael	Friedlander,	ANZGOG
Professor	Alexander	Gallus,	PREDICT
Dr	Davina	Ghersi,	ANZCTR
Associate	Professor	Peter	Gill,	SNAC
Dr	David	Goldstein,	AGITG
Dr	Geraldine	Goss,	ANZGOG
Dr	Michelle	Grogan,	ANZGOG
Dr	Andrew	Haydon,	SCOT
Dr	Elizabeth	Hovey,	ANZ	GCTG
Dr	H	Malcolm	Hudson,	Biostatistics
Dr	Monika	Janda,	COGNO
Dr	Michael	Jefford,	SCOT
Dr	David	J	Joseph,	COGNO
Dr	Andrew	Kneebone,	LAP07
Dr	Eng-Siew	Koh,	COGNO
Ms	Robyn	Leonard,	COGNO
Dr	Trevor	Leong,	AGITG
Ms	Karen	Livingstone,	ANZGOG
Dr	Elizabeth	Lobb,	COGNO
Professor	G	Bruce	Mann,	AGITG
Professor	Ian	Marschner,	HERO-2
Dr	Nicole	McCarthy,	ANZGOG
Dr	Sue-Anne	McLachlan,	ALTG
Dr	Michael	Michael,	DECO
Dr	Linda	Mileshkin,	PORTEC-3
Professor	Michael	J	Millward,	ALTG
Dr	Jeremy	Miller,	START
Dr	Christopher	Milross,	ANZGOG
Professor	Anna	Nowak,	CATNON
Professor	Andreas	Obermair,	Oncology
Dr	Robert	Padbury,	AGITG	
Professor	Lyle	Palmer,	COGNO
Dr	Nicholas	J	Petrelli,	AGITG
Dr	Cameron	FE	Platell,	SUPER
Dr	Timothy	J	Price,	AGITG
Professor	Michael	Quinn,	ANZGOG
Dr	Kushwin	Rajamani,	FIELD
Dr	David	T	Ransom,	SCOT
Dr	Danny	Rischin,	ANZGOG
Dr	Mark	Rosenthal,	COGNO
Dr	Gail	Ryan,	COGNO
Dr	Eva	Segelov,	Quasar	2
Dr	Jennifer	A	Shannon,	Oncology
Dr	Bernard	M	Smithers,	Gastric
Dr	Ben	Solomon,	BR.24	
Dr	Nigel	A	Spry,	LAP07
Dr	Christopher	Steer,	EORTC
Dr	Andrew	R	Stevenson,	A	la	CART
Mr	Denis	Strangman,	COGNO
Mr	John	Stubbs,	ANZ	GCTG
Dr	Christopher	Sweeney,	ANZUP
Professor	William	Tarnow-Mordi,	neonatal	
trials
Dr	Niall	Tebbutt,	AGITG
Professor	Damian	Thompson,	ANZUP
Dr	Ru-Dee	Ting,	FIELD
Associate	Professor	Guy	Toner,	ANZUP
Dr	Paul	Vasey,	ANZGOG
Dr	Michell	Vaughan,	ANZGOG
Dr	David	G	Walker,	COGNO
Dr	Neil	Wetzig,	SNAC
Dr	Desmond	Yip,	SCOT
Professor	John	Zalcberg,	AGITG
EXtErnAL	commIttEES
John	simes
ANZ	Breast	Cancer	Trials	Group	scientific	
advisory	committee
Aspirin	to	Prevent	Recurrent	Venous	
Thrombo-embolism	(aSpire)	trial	
management	committee	(chair)
Australasian	Gastro-Intestinal	Trials	Group	
(agitg)	scientific	advisory	committee,	
operations	executive	committee,	MAX	trial	
management	committee,	Quasar	2	trial	
management	committee,	Da	Vinci	trial	
management	committee
Australian	New	Zealand	Clinical	Trials	
Registry	policy	advisory	committee
Cancer	Clinical	Trials	Development	Unit	
(ctdu)	advisory	committee,	management	
committee	and	health	economics	advisory	
committee
Cancer	Institute	NSW	board
Cholesterol	Treatment	Trialists’	
Collaboration	(joint	coordinator)
Cochrane	Collaboration	prospective	meta-
analysis	methods	working	group
Cooperative	Trials	Group	for	Neuro-
Oncology	(cogno)	scientific	advisory	
committee	(deputy	chair)
Benefits	of	Oxygen	Saturation	Targeting	
(booSt	II)	trial	management	committee
Fenofibrate	Intervention	and	Event	
Lowering	in	Diabetes	(field)	management	
committee,	executive,	and	cost-
effectiveness	subcommittee
Intensive	Blood	Pressure	Reduction	
for	Acute	Cerebral	Haemorrhage	Trial	
(interact)	safety	and	data	monitoring	
committee	(chair)
International	Breast	Cancer	Intervention	
Study	(ibiS-II)	international	steering	
committee
International	Trials	of	Aspirin	to	Prevent	
Recurrent	Venous	Thrombo-Embolism	
(inSpire)	steering	committee	(chair)
Long-term	Intervention	with	Pravastatin	
in	Ischaemic	Disease	(lipid)	management	
committee,	executive,	samples	
subcommittee
National	Health	and	Medical	Research	
Council	large-scale	clinical	trials	committee	
(chair)
nhmrc	Clinical	Trials	Centre	management	
review	committee	and	scientific	advisory	
committee
Percutaneous	Coronary	Angioplasty	versus	
Thrombolysis	(pcat)	collaborative	group	
(co-coordinator)
Polypill	trials	safety	and	data	monitoring	
committee	(chair)
Sentinel	Biopsy	versus	Axillary	Clearance	
(Snac)	trial	management	committee
Trials associate	editor
Virtual	Coordinating	Centre	for	International	
Collaborative	Cardiovascular	Research	
(vigour)	statistical	group	(chair)	and	a	
vigour	leader
anthony	keech
Asian-Pacific	Society	of	Atherosclerosis	
and	Vascular	Disease	Prevention	executive	
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committee	(APSAVD)	(founding	member	
and	treasurer)
Asia-Pacific	Study	on	CHD	Risk	Factor	
Intervention	(aSpac)	management	
committee	(principal	investigator	and	study	
chairman)
bliSS	study	safety	and	data	monitoring	
committee	(chairman)
Cardiac	Society	of	Australia	and	New	
Zealand	clinical	trials	working	group	
scientific	committee	(chairman)
Cholesterol	Treatment	Trialists’	
Collaboration	(joint	coordinator	and	
convenor)
Fenofibrate	Intervention	and	Event	
Lowering	in	Diabetes	(field)	management	
committee	(principal	investigator	and	
study	chairman),	ophthalmology	substudy	
committee,	scientific	substudies	committee,	
cost-effectiveness	substudies	committee
Heart	Protection	Study	(HPS)	steering	
committee,	executive	committee	(co-
principal	investigator)
International Journal of Cardiology	clinical	
trials	editor
iSiS	Trials	Group	steering	committee
Long-term	Intervention	with	Pravastatin	
in	Ischaemic	Disease	(lipid)	study	
management	committee,	executive,	and	
quality	assurance	subcommittee
nhmrc	Clinical	Trials	Centre	management	
review	committee	and	scientific	advisory	
committee
National	Health	and	Medical	Research	
Council	training	awards	committee
NSW	Department	of	Health	shared	
assessment	committee
PLoS Medicine	editorial	board
Prospective	Pravastatin	Pooling	(PPP)	
project	international	steering	committee
Royal	Prince	Alfred	Hospital	clinical	trials	
(ethics)	subcommittee
University	of	Sydney	College	of	Health	
Sciences	board	of	postgraduate	studies
University	of	Sydney	Faculty	of	Medicine	
budget	advisory	committee	and	faculty	
awards	committee,	Department	of	Public	
Health	research	committee
Virtual	Coordinating	Centre	for	International	
Collaborative	Cardiovascular	Research	
(vigour)
lisa	askie
Antenatal	Magnesium	Sulphate	prior	to	
Preterm	Birth	for	Neuroprotection	of	the	
Fetus	infant	and	child	national	clinical	
practice	guidelines,	executive	panel	member
Benefits	of	Oxygen	Saturation	Targeting	
(booSt)	II	trial	management	committee
Cochrane	Collaboration	handbook	advisory	
group
Cochrane	Collaboration	prospective	
meta-analysis	methods	working	group	
(coordinator)
Early	Prevention	of	Childhood	Obesity	
(epoch)	prospective	meta-analysis	
collaboration	steering	committee,	member
International	Clinical	Trials	Registry	
Platform,	World	Health	Organization,	best	
practice	group
International	Forum	for	Standards	for	
Research	in	Children	sample	size	and	
data	safety	monitoring	committee	
subcommittee	member
Meta-Analysis	of	Preterm	Patients	
on	Inhaled	Nitric	Oxide	(mappino)	
Collaboration	steering	group
Neonatal	Oxygen	Prospective	Meta-
analysis	(NeOProM)	collaboration	steering	
committee	(chair)
Perinatal	Antiplatelet	Review	of	
International	Studies	(pariS)	collaboration	
steering	committee,	writing	committee	
(chair)
PLoS ONE	academic	editor
Prevention	of	Ventilation	Induced	Lung	
Injury	Collaborative	Group	(Previlig)	
steering	committee
Royal	Prince	Alfred	Hospital	clinical	trials	
(ethics)	subcommittee
amy	boland
Australian	and	New	Zealand	Germ	Cell	Trials	
Group	(anz	gctg)	operations	executive	
committee
Australian	&	New	Zealand	Urogenital	and	
Prostate	Cancer	Trials	Group	(anzup)	
operations	executive	committee,	
Accelerated	BEP,	Aprepitant	for	Germ	Cell	
Chemotherapy,	Chemo	&	Cognition,	Sorce	
and	everSun	trial	management	committees
mark	Chatfield
Accelerated	BEP	trial	management	
committee
Aprepitant	trial	management	committee
Australian	and	New	Zealand	Urogenital	
and	Prostate	Cancer	Trials	Group	(anzup)	
scientific	advisory	committee
Chris	brown
Cooperative	Trials	Group	for	Neuro-
Oncology	(cogno)	scientific	advisory	
committee
Australasian	Lung	Cancer	Trials	Group	
scientific	advisory	committee,	operational	
executive	committee
xanthi	Coskinas
Sentinel	Node	Biopsy	versus	Axillary	
Clearance	(Snac)	and	Snac	2	trial	
management	committees
Peta	forder
Australasian	Lung	Cancer	Trials	Group	
scientific	advisory	committee,	operational	
executive	committee
Biostatistics	Collaboration	of	Australia	
teaching	committee
Cancer	Institute	NSW	Partnership	
operational	executive	committee
Laparoscopic	Approach	to	Carcinoma	of	
the	Endometrium	(lace)	management	
committee
Corona	gainford
Australasian	Gastro-Intestinal	Trials	Group	
(agitg)	trials	operations	committee	and	
scientific	advisory	committee
Australia	New	Zealand	Gynaecological	
Oncology	Group	(anzgog)	trials	operations	
committee
Cancer	Institute	NSW	executive	committee,	
infrastructure	grant	subcommittee	and	
audit	subcommittee
tripod	trial	management	committee	(chair)
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Adjuvant	chemotherapy	versus	surgery	
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Gastro-Intestinal	Trials	Group	(agitg)	
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Australasian	KidneyTrials	Network	advisory	
board
Australia	New	Zealand	Gynaecological	
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Benefit,	Outback	trial	management	
committees
Australian	&	New	Zealand	Urinary	and	
Prostate	Trials	Group	(anzup)	scientific	
advisory	committee	and	Accelerated	BEP	
and	everSun	trial	management	committees
Australian	New	Zealand	Breast	Cancer	Trials	
Group	acientific	advisory	committee	and	
later	NeoGem	ANZ001	trial	management	
committee
Avastin	use	in	platinum-resistant	epithelial	
ovarian	cancer	safety	and	data	monitoring	
committee	
Biostatistics	Collaboration	of	Australia	
steering	committee	and	teaching	
committee
gcig/gineco	gcig	intergroup	study	
comparing	pegylated	liposomal	doxorubicin	
(Caelyx)	and	carboplatin	versus	paclitaxel	
and	carboplatin	in	patients	with	epithelial	
ovarian	cancer	trial	management	committee
lacc	trial	management	committee
lace	trial	management	committee
Medical Journal of Australia	consultant	
statistician
Multicentre	study	of	RAD	in	the	treatment	
of	pulmonary	fibrosis	safety	and	data	
monitoring	committee	
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nmrc	Singapore	Indomethacin	study	for	
closure	of	PDA	safety	data	and	monitoring	
committee
NSW	Health	Eastern	Sydney	Area	ethics	
committee	clinical	trials	subcommittee
Oxygen	versus	air	in	oxygen-naïve	patients	
with	refractory	dyspnoea	and	PaO2>55	
safety	and	data	monitoring	committee	
Snac	trial	management	committee	
Testosterone	undecanoate	in	obese	men	as	
adjuvant	therapy	for	a	weight	loss	program	
safety	and	data	monitoring	committee.	
Trastuzumab	with	a	fluoropyrimidine	and	
cisplatin	versus	chemotherapy	alone	as	first-
line	therapy	in	patients	with	HER2	positive	
advanced	gastric	cancer	safety	and	data	
monitoring	committee	
Westmead	Cancer	Care	Joint	Radiation	
Oncology	Centre	research	committee
reena	gill
Australasian	Gastro-Intestinal	Trials	Group	
(agitg),	operations	executive	committee	
and	CO.20	trial	management	committee	
wendy	Hague
Aspirin	to	Prevent	Recurrent	Venous	
Thromboembolism	(aSpire)	management	
committee
Benefits	of	Oxygen	Saturation	Targeting	
(booSt)	II	management	committee
International	Neonatal	Immunotherapy	
Study	(iniS)	Australian	and	New	Zealand	
management	committee
Long-Term	Intervention	with	Pravastatin	
in	Ischaemic	Disease	(lipid)	management	
committee
Australian	Placental	Transfusion	Study	
(aptS)	management	committee
Australasian	Gastro-Intestinal	Trials	Group	
(agitg)	trials	operations	committee
Australia	New	Zealand	Gynaecological	
Oncology	Group	(anzgog)	trials	operations	
committee
Cancer	Institute	NSW	infrastructure	grant	
steering	committee	and	human	research	
ethics	committee
adrienne	kirby
Australian	Placental	Transfusion	Study	
(aptS)	management	committee
Biostatistics	Collaboration	of	Australia	
teaching	committee
Benefits	of	Oxygen	Saturation	Targeting	
(booSt)	II	trial	management	committee
Long-Term	Intervention	with	Pravastatin	
in	Ischaemic	Disease	(lipid)	management	
committee
erica	Jobling
Biostatistics	Collaboration	of	Australia	
writing	group
National	Curriculum	for	Entomology	
evaluation	committee
Julie	martyn
Australia	New	Zealand	Gynaecological	
Oncology	Group	(anzgog)	research	
advisory	committee,	operations	executive	
committee	and	study	coordinators	
committee
Cancer	Institute	NSW	infrastructure	grant	
subcommittee
Gynecological	Cancer	Intergroup	(gcig)	
harmonisation	and	statistics	committee	
(chair)
icon-7,	portec-3	and	ovar-16	
international	steering	committees
tripod,	Symptom	Benefit,	portec-3	and	
Outback	trial	management	committees
danielle	miller
Australasian	Gastro-Intestinal	Trials	Group	
(agitg)	scientific	advisory	committee,	
operations	executive	committee,	biological	
subcommittee	
Australasian	Lung	Cancer	Trials	Group	
(altg)	operations	executive
Australian	and	New	Zealand	Germ	Cell	Trials	
Group	(anz	gctg)operations	executive	
Australian	New	Zealand	Breast	Cancer	Trials	
Group	(anz	bctg)
Cancer	Australia	Clinical	Trials	Development	
Unit	(ctdu)	program	management	
committee,	strategic	advisory	committee	
and	health	economics	subcommittee
Primary	Care	Collaborative	Cancer	Clinical	
Trials	Group	(PC4)	operations	team	and	
scientific	advisory	committee
rebecca	mister
Aspirin	to	Prevent	Recurrent	Venous	
Thromboembolism	(aSpire)	management	
committee
Julie	martyn
Australia	New	Zealand	Gynaecological	
Oncology	Group	(anzgog)	research	
advisory	committee,	study	coordinators	
committee
Gynaecological	Cancer	Intergroup	(gcig)	
harmonization	working	group
rhana	Pike
Australasian	Medical	Writers	Association	
executive	committee	(vice-president)
ann	ratcliffe
Co-operative	Trials	Group	for	Neuro-
Oncology	(cogno)	operations	executive	
and	scientific	advisory	committees
kathleen	scott
NSW	Cancer	Institute	partnership	
operations	executive	committee
Co-operative	Trials	Group	for	Neuro-
Oncology	(cogno)	operations	executive	
and	scientific	advisory	committees
martin	stockler
Australasian	Leukaemia	&	Lymphoma	Group	
safety	and	data	monitoring	committee
Australasian	Lung	Cancer	Trials	Group	
scientific	advisory	committee	
Australia	Asia-Pacific	Clinical	Oncology	
Research	Development	(acord)	workshop	
steering	committee	(co-convenor)
Australia	New	Zealand	Gynaecological	
Oncology	Group	(anzgog)	research	
advisory	committee	
Australian	and	New	Zealand	Breast	Cancer	
Trials	Group	(anz	bctg)	scientific	advisory	
committee	
Cancer	Council	Australia	national	oncology	
education	committee	
Cancer	Council	Australia	national	oncology	
education	committee
Cancer	Trials	NSW	steering	committee,	trial	
selection	committee	(chair),	centre	selection	
committee
Cochrane	Collaboration	advanced	breast	
cancer	working	party
Journal of Clinical Oncology editorial	board	
member
National	Breast	Cancer	Centre	eClinical 
Updates	editorial	board
National	Breast	Cancer	Centre	clinical	
updates	advisory	committee
National	Breast	Cancer	Centre	hormone	
therapy	working	group	(chair)	and	
information	advisory	group	(chair)
National	Breast	Cancer	Foundation	Strategic	
research	advisory	panel
National	Cancer	Institute	(NCI)	Intergroup	
health	related	quality-of-life	committee
nhmrc	grant	review	panels	for	oncology	
and	palliative	care	strategic	grants
University	of	Sydney	Faculty	of	Medicine	
oncology	block	committee	(chair),	EBM	
in	GMP3/4	(chair),	evidence-based	
medicine	resource	group,	integrated	clinical	
attachment	committee	and	uSmp	cancer	
planning	committee
burcu	vachan
Australasian	Gastro-Intestinal	Trials	Group	
(agitg)	operations	executive,	biological	
subcommittee
Australian	and	New	Zealand	Germ	Cell	Trials	
Group	(anz	gctg)	operations	executive	and	
executive
Australia	New	Zealand	Gynaecological	
Oncology	Group	(anzgog)	operations	
executive	and	research	advisory	committee
Australasian	Lung	Cancer	Trials	Group	
(altg)	operations	executive	and	scientific	
advisory	committee
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Australian	New	Zealand	Breast	Cancer	Trials	
Group	(anz	bctg)
Cancer	Institute	NSW	infrastructure	grant	
subcommittee
Cancer	Institute	NSW	partnership	grant	
operational	executive	committee
kate	wilson
Australasian	Gastro-Intestinal	Trials	Group	
(agitg)	scientific	advisory	committee,	
operations	executive	committee,	study	
coordinators	subcommittee	(chair),	annual	
scientific	meeting	committee;	and	MAX,	
Quasar	2,	attax,	deco,	and	Da	Vinci	trial	
management	committees	
Cancer	Institute	NSW	infrastructure	grant	
subcommittee
nicole	wong
Australasian	Gastro-Intestinal	Trials	Group	
(agitg)	operations	executive	committee,	
petacc	6,	SCOT	and	attax	3	trial	
management	committees
sonia	yip
Australasian	Gastro-Intestinal	Trials	Group	
(agitg)	scientific	advisory	committee,	
operations	executive,	biological	
subcommittee	
Australian	and	New	Zealand	Urogenital	
and	Prostate	Group	(anzup)	operations	
executive	
Australia	New	Zealand	Gynaecological	
Oncology	Group	(anzgog)	operations	
executive	and	research	advisory	committee
Australasian	Lung	Cancer	Trials	Group	
(altg)	operations	executive	and	scientific	
advisory	committee
Cooperative	Trials	Group	for	Neuro-
Oncology	(cogno)	operations	excutive	and	
scientific	advisory	committee.
AcAdEmIc	tEAcHIng
John	simes
Decision	analysis,	Master	of	Public	Health	
and	Master	of	Medicine,	University	of	
Sydney
anthony	keech
Controlled	clinical	trials,	Master	of	Public	
Health	and	Master	of	Medicine,	University	of	
Sydney	(convener)
University	of	Sydney	Graduate	Medical	
Program
Cardiology	training,	Royal	Prince	Alfred	
Hospital
Clinical	tutor,	Royal	Prince	Alfred	Hospital
lisa	askie
Advanced	clinical	data	management,	
Master	of	Health	Information	Management,	
University	of	Sydney
Advanced	systematic	reviews,	Master	of	
Clinical	Epidemiology,	University	of	Sydney	
(co-coordinator)
Controlled	clinical	trials,	Master	of	Public	
Health,	University	of	Sydney
Evidence-based	medicine	in	the	clinical	
years,	University	of	Sydney	Medical	Program
elizabeth	barnes
Advanced	clinical	trials,	Biostatistics	
Collaboration	of	Australia
Basic	sciences	in	oncology,	NSW	Cancer	
Council
Controlled	clinical	trials,	Master	of	Public	
Health	and	Master	of	Medicine,	University	
of	Sydney
Principles	of	statistical	inference,	
Biostatistics	Collaboration	of	Australia
Prunella	blinman
University	of	Sydney	Medical	Program
Christopher	brown
Controlled	clinical	trials,	Master	of	Public	
Health	and	Master	of	Medicine,	University	
of	Sydney
Basic	sciences	in	oncology,	NSW	Cancer	
Council
mark	Chatfield
Advanced	clinical	trials,	Biostatistics	
Collaboration	of	Australia
Peta	forder
Advanced	clinical	trials,	Biostatistics	
Collaboration	of	Australia
Australia	&	Asia-Pacific	Clinical	Oncology	
Research	Development	(ACORD)	workshop	
faculty
Controlled	clinical	trials,	Master	of	Public	
Health	and	Master	of	Medicine,	University	
of	Sydney
Corona	gainford
University	of	Sydney	Medical	Program
val	gebski
Advanced	clinical	trials,	Biostatistics	
Collaboration	of	Australia	(coordinator)
Basic	sciences	in	oncology,	NSW	Cancer	
Council
Controlled	clinical	trials,	Master	of	Public	
Health	and	Master	of	Medicine,	University	
of	Sydney
Radiation	oncology	training,	racr	trainees,	
Westmead	Hospital,	NSW	Cancer	Council
adrienne	kirby
Basic	sciences	in	oncology,	NSW	Cancer	
Council
Controlled	clinical	trials,	Master	of	Public	
Health	and	Master	of	Medicine,	University	
of	Sydney
Principles	of	statistical	inference,	
Biostatistics	Collaboration	of	Australia	
(coordinator)
sally	lord
Advanced	evaluation	of	diagnostic	tests,	
Master	of	Public	Health	and	Master	of	
Medicine,	University	of	Sydney
Basic	sciences	in	oncology,	NSW	Cancer	
Council
Decision	analysis,	Master	of	Public	Health	
and	Master	of	Medicine,	University	of	
Sydney
Evidence-based	medicine,	University	of	
Sydney	Medical	Program
andrew	martin
Decision	analysis,	Master	of	Public	Health	
and	Master	of	Medicine,	University	of	
Sydney
Controlled	clinical	trials,	Master	of	Public	
Health	and	Master	of	Medicine,	University	
of	Sydney
rebecca	mister
Advanced	clinical	data	management,	
Master	of	Health	Information	Management,	
University	of	Sydney
rachel	o’Connell
Principles	of	statistical	inference,	Biostatistics	
Collaboration	of	Australia
lukas	staub
Screening	and	diagnostic	test	evaluation,	
Master	of	Public	Health	and	Master	of	
Medicine,	University	of	Sydney
martin	stockler
Australia	&	Asia-Pacific	Clinical	Oncology	
Research	Development	(ACORD):	convenor	
and	chair	of	international	steering	
committee	
Making	sense	of	Cancer	Clinical	Trials	for	
NSW	Medical	Oncology	Trainees	(convenor)
Clinical	epidemiology	for	physician	trainees,	
Royal	Prince	Alfred	Hospital
Evidence-based	medicine	in	the	clinical	
years,	University	of	Sydney	Medical	Program	
(chair	and	coordinator)
Medical	oncology	clinical	training,	Royal	
Prince	Alfred	Hospital
Oncology	and	palliative	care,	University	of	
Sydney	Medical	Program	(block	chair)
Patient-based	measures,	Master	of	
Medicine,	University	of	Sydney	(course	
coordinator)
Quality	of	life	in	oncology,	Cancer	Institute	
NSW
burcu	vachan
Basic	sciences	in	oncology,	NSW	Cancer	
Council
Evidence-based	medicine,	University	of	
Sydney	Medical	Program
diana	Zannino
Advanced	clinical	trials,	Biostatistics	
Collaboration	of	Australia
Controlled	clinical	trials,	Master	of	Public	
Health	and	Master	of	Medicine,	University	
of	Sydney
Basic	sciences	in	oncology,	NSW	Cancer	
Council
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